Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 50
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of viral detection in patients with community-acquired pneumonia, An observational cohort study, Impacto de la detección viral en pacientes con neumonía comunitaria

  • Sellarès-Nadal, Júlia|||0000-0002-0209-6494
  • Burgos, Joaquín|||0000-0001-8445-3047
  • Velasquez, Fernando
  • Martin-Gomez, M. Teresa|||0000-0001-8119-8749
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Romero-Herrera, Daniel
  • Eremiev, Simeón|||0000-0002-5494-183X
  • Bosch-Nicolau, Pau|||0000-0002-7435-1829
  • Rodriguez-Pardo, Dolors|||0000-0001-6781-5405
  • Len, Oscar|||0000-0002-1819-3141
  • Falcó, Vicenç|||0000-0001-9626-0023
Purpose: The presence of a respiratory virus in patients with community-acquired pneumonia (CAP) may have an impact on the bacterial etiology and clinical presentation. In this study we aimed to assess the role of viral infection in the bacterial etiology and outcomes of patients with CAP. Methods: We performed a retrospective study of all adults hospitalized with CAP between November 2017 and October 2018. Patients were classified according to the presence of viral infection. An unvaried and a multivaried analysis were performed to identify variables associated with viral infection and clinical outcomes. Results: Overall 590 patients were included. A microorganism was documented in 375 cases (63.5%). A viral infection was demonstrated in 118 (20%). The main pathogens were Streptococcus pneumoniae (35.8%), Staphylococcus aureus (2.9%) and influenza virus (10.8%). A trend to a higher rate of S. aureus (p = 0.06) in patients with viral infection was observed. Patients with viral infection had more often bilateral consolidation patterns (17.8% vs 10.8%, p = 0.04), respiratory failure (59.3% vs 42.8%, p = 0.001), ICU admission (17.8% vs 7%, p = 0.001) and invasive mechanical ventilation (9.3% vs 2.8%, p = 0.003). Risk factors for respiratory failure were chronic lung disease, age >65 years, positive blood cultures and viral infection. Influenza, virus but no other respiratory viruses, was associated with respiratory failure (OR, 3.72; 95% CI, 2.06-6.73). Conclusions: Our study reinforces the idea that co-viral infection has an impact in the clinical presentation of CAP causing a more severe clinical picture. This impact seems to be mainly due to influenza virus infection., Objetivos: La presencia de virus respiratorios en pacientes con neumonía adquirida en la comunidad (NAC) puede tener un impacto en la etiología bacteriana y en la presentación clínica. El objetivo de este estudio fue evaluar el papel de la infección viral en la etiología bacteriana y la evolución de los pacientes con NAC. Métodos: Realizamos un estudio retrospectivo de todos los adultos hospitalizados con diagnóstico de NAC entre noviembre de 2017 y octubre de 2018. Los pacientes fueron clasificados según la presencia de infección viral. Se realizó un análisis univariado y multivariado para identificar variables asociadas con la infección viral y la evolución clínica. Resultados: En total se incluyeron 590 pacientes. Se documentó el microorganismo en 375 casos (63,5%). Se demostró una infección viral en 118 (20%). Los principales patógenos fueron S. pneumoniae (35,8%), S. aureus (2,9%) y virus de la influenza (10,8%). Se observó una tendencia a una mayor tasa de S. aureus (p = 0,06) en pacientes con infección viral. Los pacientes con infección viral tenían con mayor frecuencia patrones de consolidación bilateral (17,8% vs 10,8%; p = 0,04), insuficiencia respiratoria (59,3% vs 42,8%; p = 0,001), ingreso en UCI (17,8% vs 7%; p = 0,001) y necesidad de ventilación mecánica invasiva (9,3% vs 2,8%; p = 0,003). Los factores de riesgo para insuficiencia respiratoria fueron enfermedad pulmonar crónica, edad >65 años, hemocultivos positivos e infección viral. El virus de la influenza, pero ningún otro virus respiratorio, se asoció con insuficiencia respiratoria (OR: 3,72; IC 95%: 2,06-6,73). Conclusiones: Nuestro estudio refuerza la idea de que la infección viral tiene un impacto en la presentación clínica de la NAC provocando un cuadro clínico más grave. Este impacto parece deberse principalmente a la infección por el virus de la influenza.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Spain

  • Palacios-Baena, Z.R.
  • Calvo-Montes, J.
  • Martínez-Martínez, L.
  • Cantón, R.
  • Pitart, Cristina|||0000-0002-3083-7915
  • Bou, German|||0000-0001-8837-0062
  • Pascual, Á.
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • Alemán, Araceli
  • Rivera, A.
  • Pintado, Vicente
  • Ruiz-Garbajosa, P.
  • Gracia-Ahufinger, I.
  • Quintano, F.T.
  • Clavijo, E.
  • Arias, M.
  • Del Pozo, Jose Luis|||0000-0002-5402-3334
  • Lecuona, M.
  • Cercenado, Emilia|||0000-0002-5279-3773
  • Salamanca-Rivera, Elena
  • Cañada-García, Javier E.
  • Moure García, Zaira
  • Pérez-Vázquez, María
  • Ruiz-Carrascoso, Guillermo
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Mulet, Xavier
  • González-López, Juanjo|||0000-0003-2419-5909
  • Sivianes, Fran
  • Delgado-Valverde, Mercedes
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
  • Canut-Blasco, Andrés
  • Jorge Arribas García
  • Ayestarán, Ignacio
  • Gutiérrez, David
  • Gijón, Desirèe
  • Roca, Ignasi|||0000-0002-1800-1576
  • Nuvials, Xavier|||0000-0002-6648-2394
  • Viñado, Belén|||0000-0001-6212-5886
  • González, Mónica
  • Suberviola Canas, Borja
  • Maria Elicier Cano García
  • Tinajas, Almudena
  • García Bravo, Moises
  • de Tuesta Díaz, Jose Luis
  • Vidal-García, Matxalen
  • Gomáriz Díaz, María
  • Pérez del Molino Bernal, Mª Luisa
  • Coira Nieto, Amparo
  • Rodríguez Tarazona, Raquel Elisa
  • Arenal Andrés, Noelia
  • Paz Vidal, Mª Isabel
  • Rey-Cao, Sonia
  • Martínez Lamas, Lucía
  • Cabezas Fernández, Mª Teresa
  • Cabeza, Mª Isabel
  • Roldán, Carolina
  • Liébana, Carmen
  • Galán Sánchez, Fátima
  • GarcíaSánchez, Federico Juan Manuel
  • Chueca, Natalia|||0000-0002-3420-3290
  • Mora, Laura
  • Martí Salas, Carmina
  • Quesada, Dolores
  • Casabella Pernas, Antonio|||0000-0002-2534-3689
  • Sanchez, Nerea
  • Aldea Mansilla, Carmen
  • Rodríguez Escudero, M. José
  • Huertas, María
  • Gaitán Durán, Jorge
  • Esparcia Rodríguez, Oscar
  • Sainz de Baranda, Caridad
  • Riquelme Bravo, Eva
  • Hernando, Susana
  • Sánchez Arroyo, Rafael
  • Iglesias Nuñez, Nuria
  • Villa, Jennifer
  • Clapés Sanchez, Ester
  • Gimeno, Adelina
  • López Soria, Leyre
  • Barrios Andrés, Jose Luis
  • García Garrote, Fernando
  • Palop, Begoña
  • Valverde Troya, Miriam
  • García-Gonzàlez, Merce
  • Belles, Alba
  • Azcona, José Manuel
  • López-Calleja, Ana Isabel
  • Pérez Moreno, Mar Olga|||0000-0002-4216-4965
  • Fernández Natal, Isabel
  • Garduno Eseverri, Eugenio
  • Sánchez Benito, Rosario
  • de la Iglesia, Pedro
  • Illescas, Soledad
  • Garcia Agudo, Lidia
  • Frasquet, Juan
  • Leiva, José
  • Giner, Salvador
  • López-Urrutia Lorente, Luis
  • Perez Arellano, Jose Luis
  • del Rosario, Cristobal
  • Ortega Lafont, Pilar
  • Martínez Ramírez, Mariela
Background: Community-acquired (CA) and healthcare-associated (HCA) infections caused by carbapenemase-producing Enterobacterales (CPE) are not well characterized. The objective was to provide detailed information about the clinical and molecular epidemiological features of nosocomial, HCA and CA infections caused by carbapenemase-producing Klebsiella pneumoniae (CP-Kp) and Escherichia coli (CP-Ec). Methods: A prospective cohort study was performed in 59 Spanish hospitals from February to March 2019, including the first 10 consecutive patients from whom CP-Kp or CP-Ec were isolated. Patients were stratified according to acquisition type. A multivariate analysis was performed to identify the impact of acquisition type in 30-day mortality. Results: Overall, 386 patients were included (363 [94%] with CP-Kp and 23 [6%] CP-Ec); in 296 patients (76.3%), the CPE was causing an infection. Acquisition was CA in 31 (8.0%) patients, HCA in 183 (47.4%) and nosocomial in 172 (48.3%). Among patients with a HCA acquisition, 100 (54.6%) had been previously admitted to hospital and 71 (38.8%) were nursing home residents. Urinary tract infections accounted for 19/23 (82.6%), 89/130 (68.5%) and 42/143 (29.4%) of CA, HCA and nosocomial infections, respectively. Overall, 68 infections (23%) were bacteremia (8.7%, 17.7% and 30.1% of CA, HCA and nosocomial, respectively). Mortality in infections was 28% (13%, 14.6% and 42.7% of CA, HCA and nosocomial, respectively). Nosocomial bloodstream infections were associated with increased odds for mortality (adjusted OR, 4.00; 95%CI 1.21-13.19). Conclusions: HCA and CA infections caused by CPE are frequent and clinically significant. This information may be useful for a better understanding of the epidemiology of CPE.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Host-dependent editing of SARS-CoV-2 in COVID-19 patients

  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Piñana, Maria|||0000-0002-4766-2613
  • Campos, Carolina|||0000-0002-0132-7027
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Andrés, Cristina|||0000-0002-3200-0895
  • Abril, Josep Francesc|||0000-0001-7793-589X
  • Codina, María Gema|||0000-0002-5313-5086
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Sulleiro, Elena|||0000-0002-9783-6060
  • Joseph-Munné, Joan
  • Saubi, Narcis|||0000-0001-5493-1044
  • Colomer Castell, Sergi|||0000-0002-0307-7455
  • Martin, Mari Carmen|||0000-0003-1327-8813
  • Castillo, Carla
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Quer, Josep|||0000-0003-0014-084X
A common trait among RNA viruses is their high capability to acquire genetic variability due to viral and host mechanisms. Next-generation sequencing (NGS) analysis enables the deep study of the viral quasispecies in samples from infected individuals. In this study, the viral quasispecies complexity and single nucleotide polymorphisms of the SARS-CoV-2 spike gene of coronavirus disease 2019 (COVID-19) patients with mild or severe disease were investigated using next-generation sequencing (Illumina platform). SARS-CoV-2 spike variability was higher in patients with long-lasting infection. Most substitutions found were present at frequencies lower than 1%, and had an A → G or T → C pattern, consistent with variants caused by adenosine deaminase acting on RNA-1 (ADAR1). ADAR1 affected a small fraction of replicating genomes, but produced multiple, mainly non-synonymous mutations. ADAR1 editing during replication rather than the RNA-dependent RNA polymerase (nsp12) was the predominant mechanism generating SARS-CoV-2 genetic variability. However, the mutations produced are not fixed in the infected human population, suggesting that ADAR1 may have an antiviral role, whereas nsp12-induced mutations occurring in patients with high viremia and persistent infection are the main source of new SARS-CoV-2 variants.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Effectiveness of oral step-down therapy and early oral switch for bloodstream infections caused by Enterobacterales: A post hoc emulation trial of the SIMPLIFY trial

  • Rando, Emanuele
  • Delgado-Valverde, Mercedes
  • Goikoetxea-Aguirre, Josune
  • Guio Carrión, Laura
  • Blanco-Vidal, María José
  • Barrios Andrés, José Luis
  • Pérez-Rodríguez, María Teresa
  • Martínez-Lamas, Lucía
  • Arnaiz de Las Revillas, Francisco
  • Armiñanzas, Carlos
  • Ruiz de Alegría, Carlos
  • Jiménez-Aguilar, Patricia
  • Martínez-Rubio, María del Carmen
  • Sáez-Béjar, Carmen
  • Cuevas, Carmen de las
  • Martín-Aspas, Andrés
  • Galán, Fátima
  • Yuste, José Ramón
  • Leiva-León, José
  • Bou, Germán
  • Capón González, Patricia
  • Boix-Palop, Lucía
  • Xercavins-Valls, Mariona
  • Goenaga Sánchez, Miguel Ángel
  • Anza, Diego Vicente
  • Castón, Juan José
  • Recio Rufián, Manuel
  • Merino, Esperanza
  • Rodríguez, Juan Carlos
  • Loeches, Belén
  • Rosso-Fernández, Clara
  • Bravo-Ferrer, José María
  • Retamar-Gentil, Pilar
  • Rodríguez-Baño, Jesús
  • López-Cortés, Luis Eduardo
[Objectives] We investigated the effectiveness of early oral switch for treating Enterobacterales bloodstream infection (BSI) by performing a post hoc emulation trial of the SIMPLIFY trial., [Methods] We conducted a post hoc analysis of a randomized controlled trial. We specified the target trial characteristics selecting patients who achieved clinical stability on day 5. We categorized patients into those who switched on day 5 and those who continued intravenously. The primary outcome was clinical cure at the test of cure. We set a propensity score for being switched on day 5 to reduce confounding. We ran simple, not-propensity-adjusted, and propensity-adjusted logistic regression models to ascertain the association of switch on day 5 with clinical cure., [Results] Among 303 patients who achieved clinical stability on day 5, 110 (36.3%) were switched orally on day 5, and 193 (63.7%) were kept intravenously. We detected no difference in clinical cure between those switched on day 5 and those continued intravenously (risk ratios 1.04, 95% confidence intervals [CI] 0.98-1.10). Propensity-adjusted analysis did not show an association between day 5 switch and clinical cure (OR 2.10, 95% CI 0.96-7.41)., [Conclusion] Oral step-down therapy on day 5 was not associated with worse clinical cure for Enterobacterales BSI., The study was funded by the Plan Nacional de I+D+i 2013‐2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001; 0002; 0003; 0005; 0007; 0008; 0009; 0011; 0012; 0015); Spanish Clinical Research and Clinical Trials Platform, (SCReN, PT13/0002/0010 and PT17/0017/0012, and PI15/00439), co‐financed by European Union; European Development Regional Fund “A way to achieve Europe,” Operative Program Intelligence Growth 2014‐2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Fosfomycin in bacteraemic urinary tract infection due to multidrug-resistant Escherichia coli: insights of post hoc DOOR analysis of the FOREST trial

  • Sojo-Dorado, Jesús
  • López-Hernández, Inmaculada
  • Gutiérrez-Gutiérrez, Belén
  • Rosa-Riestra, Sandra de la
  • Docobo-Pérez, Fernando
  • Hernánez-Torres, Alicia
  • Pascual, Álvaro
  • Rodríguez-Baño, Jesús
[Purpose] A post hoc analysis of data from a previously published clinical trial was conducted using the desirability of outcome ranking (DOOR) methodology with the aim provide additional information on the use of fosfomycin for the treatment of bacteraemic urinary tract infection (BUTI) caused by multi-drug-resistant (MDR) E. coli., [Methods] Three DOOR systems with five, six and seven categories, respectively were developed. Safety and efficacy were prioritised in all rankings, but step down to oral therapy and exposure to antibiotics with lower ecological impact were also considered in DOOR-6 and DOOR-7. The probability that a patients assigned to fosfomycin was classified into a more desirable outcome category was calculated for the three DOOR definitions. Subgroups analyses and an ordinal logistic regression model were also performed., [Results] Data from 143 participants were analysed. The probability of having a more desirable outcome after treatment with fosfomycin versus the comparators was 0.44 (95% CI 0.36 − 0.52) for DOOR-5; 0.50 (95% IC 0.42 − 0.58) using DOOR-6 and 0.61 (95% CI 0.53–0.69) with DOOR-7. In subgroups, the highest probability of having a better DOOR with fosfomycin was seen in the clinically evaluable population and among patients without chronic heart disease or renal insufficiency for the DOOR-7 definition., [Conclusions] DOOR analysis could be applied to the FOREST trial data; the results were somehow different for the different DOOR systems used. Overall, fosfomycin was favoured when oral step-down treatment and use of antibiotics with lower ecological impact were included., The study was funded by grants RD16/0016/0001, 0002, 0003, 0005, 0007, 0008, 0009, 0011, 0012, and 0015 from Plan Nacional de Investigación, Desarrollo e Innovación (I + D + i) 2013 to 2016 and the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI); PT13/0002/0010 and PT17/0017/0012 from the Spanish Clinical Research and Clinical Trials Platform (SCReN); and PI 13/01282 co-financed by the European Development Regional Fund “A Way to Achieve Europe” and Operative Program Intelligence Growth 2014 to 2020. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Insights into immune evasion of human metapneumovirus: novel 180- and 111-nucleotide duplications within viral G gene throughout 2014-2017 seasons in Barcelona, Spain

  • Piñana, M.
  • Vila, J.
  • Maldonado, C.
  • Galano-Frutos, J.J.
  • Valls, M.
  • Sancho, J.
  • Nuvials, F.X.
  • Andrés, C.
  • Martín-Gómez, M.T.
  • Esperalba, J.
  • Codina, M.G.
  • Pumarola, T.
  • Antón, A.
Background: Human metapneumovirus (HMPV) is an important aetiologic agent of respiratory tract infection (RTI). This study aimed to describe its genetic diversity and clinical impact in patients attended at a tertiary university hospital in Barcelona from the 2014-2015 to the 2016-2017 seasons, focusing on the emerging duplications in G gene and their structural properties. Methods: Laboratory-confirmed HMPV were characterised based on partial-coding F and G gene sequences with MEGA.v6.0. Computational analysis of disorder propensity, aggregation propensity and glycosylation sites in viral G predicted protein sequence were carried out. Clinical data was retrospectively reviewed and further associated to virological features. Results: HMPV prevalence was 3%. The 180- and 111-nucleotide duplications occurred in A2c lineage G protein increased in prevalence throughout the study, in addition to short genetic changes observed in other HMPV lineages. The A2c G protein without duplications was calculated to protrude over F protein in 23% of cases and increased to a 39% and a 46% with the 111- and 180-nucleotide duplications, respectively. Children did not seem to be more affected by these mutant viruses, but there was a strong association of these variants to LRTI in adults. Discussion: HMPV presents a high genetic diversity in all lineages. Novel variants carrying duplications might present an evolutionary advantage due to an improved steric shielding, which would have been responsible for the reported increasing prevalence and the association to LRTI in adults.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Host-dependent editing of SARS-CoV-2 in COVID-19 patients

  • Piñana Moro, Maria
  • Campos Martinez, Carolina
  • Garcia Cehic, Damir
  • Codina Grau, Gema
  • Esperalba Esquerra, Juliana
  • Sulleiro Igual, Elena
  • Joseph Munné, Joan
  • Saubí Roca, Narcís
  • Colomer Castell, Sergi
  • Martin Perez, Maria Carmen
  • Castillo Oliveda, Carla
  • Pumarola Suñé, Tomàs
  • Rodríguez Frias, Francisco
  • Quer Sivila, Josep
  • Rando Segura, Ariadna
  • Gregori Font, Josep
  • Esteban Mur, Juan Ignacio
  • Cortese, Maria Francesca
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
SARS-CoV-2; Mutacions; Quasiespècie, SARS-CoV-2; Mutaciones; Cuasiespecie, SARS-CoV-2; Mutations; Quasispecies, A common trait among RNA viruses is their high capability to acquire genetic variability due to viral and host mechanisms. Next-generation sequencing (NGS) analysis enables the deep study of the viral quasispecies in samples from infected individuals. In this study, the viral quasispecies complexity and single nucleotide polymorphisms of the SARS-CoV-2 spike gene of coronavirus disease 2019 (COVID-19) patients with mild or severe disease were investigated using next-generation sequencing (Illumina platform). SARS-CoV-2 spike variability was higher in patients with long-lasting infection. Most substitutions found were present at frequencies lower than 1%, and had an A → G or T → C pattern, consistent with variants caused by adenosine deaminase acting on RNA-1 (ADAR1). ADAR1 affected a small fraction of replicating genomes, but produced multiple, mainly non-synonymous mutations. ADAR1 editing during replication rather than the RNA-dependent RNA polymerase (nsp12) was the predominant mechanism generating SARS-CoV-2 genetic variability. However, the mutations produced are not fixed in the infected human population, suggesting that ADAR1 may have an antiviral role, whereas nsp12-induced mutations occurring in patients with high viremia and persistent infection are the main source of new SARS-CoV-2 variants., This study was supported by the Direcció General de Recerca i Innovació en Salut (DGRIS) of the Catalan Health Ministry, Generalitat de Catalunya, through the Vall d’Hebron Institut de Recerca (VHIR); the European Regional Development Fund (ERDF) “A way to achieve Europe” by the Spanish Network for Research in Infectious Diseases [grant number REIPI RD16/0016/0003]; Instituto de Salud Carlos III [grant number FIS PI19/00301]; and Centro para el Desarrollo Tecnologico Industrial (CDTI) from the Ministry of Economic Affairs and Digital Transformation [grant number IDI-20200297].
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Periprosthetic Joint Infection Prophylaxis in the Elderly after Hip Hemiarthroplasty in Proximal Femur Fractures: Insights and Challenges

  • Escola Verge, Laura
  • Sellares Nadal, Julia
  • Corona Pérez-Cardona, Pablo Salvador
  • Almirante Gragera, Benito
  • Pigrau Serrallach, Carles
  • Rodríguez Pardo, Ma Dolores
Profilaxi antibiòtica; Hemiartroplàstia de maluc; Infecció periprotèsica de l'articulació, Profilaxis antibiótica; Hemiartroplastia de cadera; Infección de la articulación periprotésica, Antibiotic prophylaxis; Hip hemiarthroplasty; Periprosthetic joint infection, We review antibiotic and other prophylactic measures to prevent periprosthetic joint infection (PJI) after hip hemiarthroplasty (HHA) surgery in proximal femoral fractures (PFFs). In the absence of specific guidelines, those applied to these individuals are general prophylaxis guidelines. Cefazolin is the most widely used agent and is replaced by clindamycin or a glycopeptide in beta-lactam allergies. A personalized antibiotic scheme may be considered when colonization by a multidrug-resistant microorganism (MDRO) is suspected. Particularly in methicillin-resistant Staphylococcus aureus (MRSA) colonization or a high prevalence of MRSA-caused PJIs a glycopeptide with cefazolin is recommended. Strategies such as cutaneous decolonization of MDROs, mainly MRSA, or preoperative asymptomatic bacteriuria treatment have also been addressed with debatable results. Some areas of research are early detection protocols in MDRO colonizations by polymerase-chain-reaction (PCR), the use of alternative antimicrobial prophylaxis, and antibiotic-impregnated bone cement in HHA. Given that published evidence addressing PJI prophylactic strategies in PFFs requiring HHA is scarce, PJIs can be reduced by combining different prevention strategies after identifying individuals who will benefit from personalized prophylaxis., This work was supported by the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación, through the project PI15/02161 and by the Plan Nacional de I+D+i 2013-016 and ISCIIII, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economia, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003)-co-financed by European Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2014–2020.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Bioinformatic Tools for NGS-Based Metagenomics to Improve the Clinical Diagnosis of Emerging, Re-Emerging and New Viruses

  • Colomer Castell, Sergi
  • González Sánchez, Alejandra
  • Campos Martinez, Carolina
  • Garcia Cehic, Damir
  • Piñana Moro, Maria
  • Pumarola Suñé, Tomàs
  • Rodríguez Frias, Francisco
  • Quer Sivila, Josep
  • Gregori Font, Josep
  • Ibañez Lligoña, Marta
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Diagnostic tools; Metagenomics; Viruses, Herramientas diagnosticas; Metagenómica; Virus, Eines diagnòstiques; Metagenòmica; Virus, Epidemics and pandemics have occurred since the beginning of time, resulting in millions of deaths. Many such disease outbreaks are caused by viruses. Some viruses, particularly RNA viruses, are characterized by their high genetic variability, and this can affect certain phenotypic features: tropism, antigenicity, and susceptibility to antiviral drugs, vaccines, and the host immune response. The best strategy to face the emergence of new infectious genomes is prompt identification. However, currently available diagnostic tests are often limited for detecting new agents. High-throughput next-generation sequencing technologies based on metagenomics may be the solution to detect new infectious genomes and properly diagnose certain diseases. Metagenomic techniques enable the identification and characterization of disease-causing agents, but they require a large amount of genetic material and involve complex bioinformatic analyses. A wide variety of analytical tools can be used in the quality control and pre-processing of metagenomic data, filtering of untargeted sequences, assembly and quality control of reads, and taxonomic profiling of sequences to identify new viruses and ones that have been sequenced and uploaded to dedicated databases. Although there have been huge advances in the field of metagenomics, there is still a lack of consensus about which of the various approaches should be used for specific data analysis tasks. In this review, we provide some background on the study of viral infections, describe the contribution of metagenomics to this field, and place special emphasis on the bioinformatic tools (with their capabilities and limitations) available for use in metagenomic analyses of viral pathogens., This study was partially supported by Pla Estratègic de Recerca i Innovació en Salut (PERIS)—Direcció General de Recerca i Innovació en Salut (DGRIS), Catalan Health Ministry, Generalitat de Catalunya; the Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003) from the European Regional Development Fund (ERDF); Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; grants PI19/00301 and PI22/00258 from Instituto de Salud Carlos III, cofinanced by the European Regional Development Fund (ERDF); and Gilead’s biomedical research project GLD21/00006. S.C-C is a recipient of a predoctoral fellowship, FPU, from Ministerio de Universidades (FPU21/04150).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A year living with SARS-CoV-2: an epidemiological overview of viral lineage circulation by whole-genome sequencing in Barcelona city (Catalonia, Spain)

  • Piñana Moro, Maria
  • González Sánchez, Alejandra
  • Garcia Cehic, Damir
  • Esperalba Esquerra, Juliana
  • Zules Oña, Ricardo Gabriel
  • Campos Martinez, Carolina
  • Codina Grau, Gema
  • Blanco Grau, Albert
  • Colomer Castell, Sergi
  • Martin Perez, Maria Carmen
  • Castillo Oliveda, Carla
  • García-Comuñas, Karen
  • Vásquez-Mercado, Rodrigo
  • Martins-Martins, Reginald
  • Saubí Roca, Narcís
  • Pumarola Suñé, Tomàs
  • Quer Sivila, Josep
  • Campins Martí, Magda
  • Rando Segura, Ariadna
  • Borras Bermejo, Blanca
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Catalonia; SARS-CoV-2; Molecular epidemiology, Cataluña; SARS-CoV-2; Epidemiología molecular, Catalunya; SARS-CoV-2; Epidemiologia molecular, Herein, we describe the genetic diversity of circulating SARS-CoV-2 viruses by whole-genome sequencing (WGS) in Barcelona city (Catalonia, Spain) throughout the first four pandemic waves. From weeks 11/2020–24/2021, SARS-CoV-2-positive respiratory samples were randomly selected per clinical setting (80% from primary care or 20% from the hospital), age group, and week. WGS was performed following the ARTICv3 protocol on MiSeq or NextSeq2000 Illumina platforms. Nearly complete consensus sequences were used for genetic characterization based on GISAID and PANGOLIN nomenclatures. From 2475 samples, 2166 (87%) were fully sequenced (78% from primary care and 22% from hospital settings). Multiple genetic lineages were co-circulating, but four were predominant at different periods. While B.1.5 (50.68%) and B.1.1 (32.88%) were the major lineages during the first pandemic wave, B.1.177 (66.85%) and B.1.1.7 (83.80%) were predominant during the second, third, and fourth waves, respectively. Almost all (96.4%) were carrying D614G mutation in the S protein, with additional mutations that define lineages or variants. But some mutations of concern, such as E484K from B.1.351 and P.1 lineages are currently under monitoring, together with those observed in the receptor-binding domain or N-terminal domain, such as L452R and T478K from B.1.617.2 lineage. The fact that a predominant lineage was observed in each pandemic wave suggests advantageous properties over other contemporary co-circulating variants. This genetic variability should be monitored, especially when a massive vaccination campaign is ongoing because the potential selection and emergence of novel antigenic SARS-CoV-2 strains related to immunological escapement events., This work was supported by Spanish Network for the Research in Infectious Diseases: [Grant Number REIPI RD16/0016/0003]; Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business [Grant Number IDI-20200297]; Direcció General de Recerca i Innovació en Salut (DGRIS); European Development Regional Fund (ERDF) “A way to achieve Europe” by Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/0003].
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The burden of non-SARS-CoV2 viral lower respiratory tract infections in hospitalized children in Barcelona (Spain): A long-term, clinical, epidemiologic and economic study

  • Vila Soler, Jorgina
  • Lera Carballo, Esther
  • Piñana Moro, Maria
  • Rello Saltor, Victoria
  • Tobeña Rue, Marc
  • Balcells Ramirez, Joan
  • Benítez Díaz, Zaira
  • Aller Hernández, Marta Beatriz
  • Muñoz Gallarin, Rosario
  • Vázquez, Ana
  • Rodrigo Gonzalo de Liria, Carlos
  • Soler-palacín, Pere
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Cost of illness; Hospitalization; Viruses, Cost de la malaltia; Hospitalització; Virus, Coste de la enfermedad; Hospitalización; Virus, Background Viral lower respiratory tract infections (LRTI) are the leading cause of hospitalization in children. In Catalonia (Spain), information is scarce about the burden of viral LRTIs in paediatric hospitalizations. The aim of this study is to describe epidemiological, clinical, virological and economic features of paediatric hospitalizations due to viral LRTI. Methods From October 2012 to December 2020, children aged <16 years admitted to a tertiary paediatric hospital in Catalonia (Spain) with confirmed viral LRTI were included in the study. Virus seasonality, prevalence, age and sex distribution, clinical characteristics, hospital costs and bed occupancy rates were determined. Results A total of 3,325 children were included (57.17% male, 9.44% with comorbidities) accounting for 4056 hospitalizations (32.47% ≤ 12 months): 53.87% with wheezing/asthma, 37.85% with bronchiolitis and 8.28% with pneumonia. The most common virus was respiratory syncytial virus (RSV) (52.59%). Influenza A was associated with pneumonia (odds ratio [OR] 7.75) and caused longer hospitalizations (7 ± 31.58 days), while RSV was associated with bronchiolitis (OR 6.62) and was the most frequent reason for admission to the paediatric intensive care unit (PICU) (11.23%) and for respiratory support (78.76%). Male sex, age ≤12 months, chronic conditions and bronchiolitis significantly increased the odds of PICU admission. From October to May, viral LRTIs accounted for 12.36% of overall hospital bed days. The total hospitalization cost during the study period was €16,603,415. Conclusions Viral LRTIs are an important cause of morbidity, hospitalization and PICU admission in children. The clinical burden is associated with significant bed occupancy and health-care costs, especially during seasonal periods., This work was partially supported by the Spanish National R + D + I Plan 2008–2011 and by the Carlos III Health Institute, the Subdirectorate-General of Networks and Cooperative Research Centers, the Spanish Ministry of Economy and Competitiveness, the Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003), and by the Health Research Fund, the Spanish Ministry of Economy and Competitiveness (grants FIS PI14/01838 and FIS PI18/00685), and the European Regional Development Fund (ERDF). Editorial assistance for revision of the English language and edition of the manuscript was provided by Vanessa Marfil, medical writer from MSC (Spain) and funded by Sanofi.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology: Implementation and Clinical Validation

  • Calvo Lozano, Olalla
  • Sierra Montoya, Miquel
  • Soler, Maria
  • Estevez, M. Carmen
  • Chiscano Camon, Luis Silvestre
  • Ruiz Sanmartin, Adolfo
  • Ruiz Rodriguez, Juan Carlos
  • Ferrer Roca, Ricard
  • Gonzalez Lopez, Juan Jose
  • Esperalba Esquerra, Juliana
  • Fernandez Naval, Candela
COVID-19; Biosensor plasmónico; Serología, COVID-19; Biosensor plasmònic; Serologia, COVID-19; Plasmonic biosensor; Serology, Serological tests are essential for the control and management of COVID-19 pandemic (diagnostics and surveillance, and epidemiological and immunity studies). We introduce a direct serological biosensor assay employing proprietary technology based on plasmonics, which offers rapid (<15 min) identification and quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in clinical samples, without signal amplification. The portable plasmonic device employs a custom-designed multiantigen (RBD peptide and N protein) sensor biochip and reaches detection limits in the low ng mL–1 range employing polyclonal antibodies. It has also been implemented employing the WHO-approved anti-SARS-CoV-2 immunoglobulin standard. A clinical validation with COVID-19 positive and negative samples (n = 120) demonstrates its excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor as an accurate and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the disease management and for the evaluation of immunological status during vaccination or treatment., ICN2 and UVE acknowledge financial support from H2020 Research and Innovation Programme of the European Commission (H202-SC1-PHE-Coronavirus-2020, CONVAT Project, No. 101003544). The ICN2 is funded by the CERCA program/Generalitat de Catalunya and supported by the Severo Ochoa Centres of Excellence program funded by the Spanish Research Agency (AEI, grant no. SEV-2017-0706). ICN2 group is very grateful to EPI Industries (Barcelona, Spain) for its kind donation supporting our research in COVID-19. O.C.-L. acknowledges the economic support from the Spanish Ministry of Science and Innovation and the Spanish Research Agency and the European Social Fund (ESF) (ref. BES-2017-080527) linked to the TEC 2016-78515-R project Predict. A part of the work was supported by the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the EU Horizon 2020 (grant agreement No. 871029). A.T. and L.F.-B. acknowledge financial support from GENCAT-DGRIS COVID. We are indebted to all the patients who accepted to participate contributing to science advancement. We are indebted to the HCB-IDIBAPS Biobank for the human samples and data procurement and to the Fundació Glòria Soler for its support to the COVIDBANK collection. We thank the IDIBAPS Biobank for its valuable contribution to sample processing and storage. The authors acknowledge the EU Horizon 2020 Program under grant agreement no. 644956 (RAIS project) for funding the Hospital Vall d’Hebron Biobank. The VHIR-HUVH is supported by Plan Nacional de I + D + i 2013-2016 and ISCIII-Ministerio de Ciencia e Innovación, and Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003)─cofinanced by European Development Regional Fund “A way to achieve Europe,” Operative program Intelligent Growth 2014. Part of the samples and data from patients included in this study were provided by the Vall d’Hebron University Hospital Biobank (PT17/0015/0047), integrated in the Spanish National Biobanks Network, and they were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committee. The authors kindly appreciate the generous donation of samples and clinical data of the donors of the Sepsis Bank of HUVH Biobank and COVID-19 patients attended at HUVH.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Quantifying In-Host Quasispecies Evolution

  • Quer Sivila, Josep
  • Gregori Font, Josep
  • Ibañez Lligoña, Marta
Mutagenesis; Quasispecies evolution; Viral treatment, Mutagénesis; Evolución de las cuasiespecies; Tratamiento viral, Mutagènesi; Evolució de les quasiespècies; Tractament viral, What takes decades, centuries or millennia to happen with a natural ecosystem, it takes only days, weeks or months with a replicating viral quasispecies in a host, especially when under treatment. Some methods to quantify the evolution of a quasispecies are introduced and discussed, along with simple simulated examples to help in the interpretation and understanding of the results. The proposed methods treat the molecules in a quasispecies as individuals of competing species in an ecosystem, where the haplotypes are the competing species, and the ecosystem is the quasispecies in a host, and the evolution of the system is quantified by monitoring changes in haplotype frequencies. The correlation between the proposed indices is also discussed, and the R code used to generate the simulations, the data and the plots is provided. The virtues of the proposed indices are finally shown on a clinical case., This study was partially supported by Pla Estratègic de Recerca i Innovació en Salut (PERIS)—Direcció General de Recerca i Innovació en Salut (DGRIS), Catalan Health Ministry, Generalitat de Catalunya; the Spanish Network for the Research in Infectious Diseases (REIPI RD16/0016/0003) from the European Regional Development Fund (ERDF); Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; grant PI19/00301 and PI22/00258 from Instituto de Salud Carlos III cofinanced by the European Regional Development Fund (ERDF), and Gilead’s biomedical research project GLD21/00006.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Next-Generation Sequencing for Confronting Virus Pandemics

  • Quer Sivila, Josep
  • Colomer Castell, Sergi
  • Campos Martinez, Carolina
  • Piñana Moro, Maria
  • González Sánchez, Alejandra
  • Garcia Cehic, Damir
  • Pumarola Suñé, Tomàs
  • Rodríguez Frias, Francisco
  • Tabernero Caellas, David
  • Ibañez Lligoña, Marta
  • Cortese, Maria Francesca
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
COVID-19; Pandemics; Viruses, COVID-19; Pandemias; Virus, COVID-19; Pandèmies; Virus, Virus pandemics have happened, are happening and will happen again. In recent decades, the rate of zoonotic viral spillover into humans has accelerated, mirroring the expansion of our global footprint and travel network, including the expansion of viral vectors and the destruction of natural spaces, bringing humans closer to wild animals. Once viral cross-species transmission to humans occurs, transmission cannot be stopped by cement walls but by developing barriers based on knowledge that can prevent or reduce the effects of any pandemic. Controlling a local transmission affecting few individuals is more efficient that confronting a community outbreak in which infections cannot be traced. Genetic detection, identification, and characterization of infectious agents using next-generation sequencing (NGS) has been proven to be a powerful tool allowing for the development of fast PCR-based molecular assays, the rapid development of vaccines based on mRNA and DNA, the identification of outbreaks, transmission dynamics and spill-over events, the detection of new variants and treatment of vaccine resistance mutations, the development of direct-acting antiviral drugs, the discovery of relevant minority variants to improve knowledge of the viral life cycle, strengths and weaknesses, the potential for becoming dominant to take appropriate preventive measures, and the discovery of new routes of viral transmission., Pla Estratègic de Recerca i Innovació en Salut (PERIS)—Direcció General de Recerca i Innovació en Salut (DGRIS), Catalan Health Ministry, Generalitat de Catalunya; the Spanish Network for the Research in Infectious Diseases (REIPI RD16/0016/0003) from the European Regional Development Fund (ERDF; Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; grant GLD21_00006; and grant PI19/00301 from Instituto de Salud Carlos III cofinanced by the European Regional Development Fund (ERDF).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3

  • Sola-Campoy, Pedro Juan
  • Delgado-Valverde, Mercedes
  • Cano, María E.
  • Gijón, Desirèe
  • Larrosa Escartin, María Nieves
  • Gonzalez Lopez, Juan Jose
  • Cañada-Garcia, Javier E.
  • Moure Garcia, Zaira
Carbapenemases; High-risk clones; Whole genome sequencing, Carbapenemasas; Clones de alto riesgo; Secuenciación del genoma completo, Carbapenemases; Clons d'alt risc; Seqüenciació del genoma sencer, Objectives: CARB-ES-19 is a comprehensive, multicenter, nationwide study integrating whole-genome sequencing (WGS) in the surveillance of carbapenemase-producing K. pneumoniae (CP-Kpn) and E. coli (CP-Eco) to determine their incidence, geographical distribution, phylogeny, and resistance mechanisms in Spain. Methods: In total, 71 hospitals, representing all 50 Spanish provinces, collected the first 10 isolates per hospital (February to May 2019); CPE isolates were first identified according to EUCAST (meropenem MIC > 0.12 mg/L with immunochromatography, colorimetric tests, carbapenem inactivation, or carbapenem hydrolysis with MALDI-TOF). Prevalence and incidence were calculated according to population denominators. Antibiotic susceptibility testing was performed using the microdilution method (EUCAST). All 403 isolates collected were sequenced for high-resolution single-nucleotide polymorphism (SNP) typing, core genome multilocus sequence typing (cgMLST), and resistome analysis. Results: In total, 377 (93.5%) CP-Kpn and 26 (6.5%) CP-Eco isolates were collected from 62 (87.3%) hospitals in 46 (92%) provinces. CP-Kpn was more prevalent in the blood (5.8%, 50/853) than in the urine (1.4%, 201/14,464). The cumulative incidence for both CP-Kpn and CP-Eco was 0.05 per 100 admitted patients. The main carbapenemase genes identified in CP-Kpn were blaOXA–48 (263/377), blaKPC–3 (62/377), blaVIM–1 (28/377), and blaNDM–1 (12/377). All isolates were susceptible to at least two antibiotics. Interregional dissemination of eight high-risk CP-Kpn clones was detected, mainly ST307/OXA-48 (16.4%), ST11/OXA-48 (16.4%), and ST512-ST258/KPC (13.8%). ST512/KPC and ST15/OXA-48 were the most frequent bacteremia-causative clones. The average number of acquired resistance genes was higher in CP-Kpn (7.9) than in CP-Eco (5.5). Conclusion: This study serves as a first step toward WGS integration in the surveillance of carbapenemase-producing Enterobacterales in Spain. We detected important epidemiological changes, including increased CP-Kpn and CP-Eco prevalence and incidence compared to previous studies, wide interregional dissemination, and increased dissemination of high-risk clones, such as ST307/OXA-48 and ST512/KPC-3., This research was supported by grants from the Instituto de Salud Carlos III (numbers PI18CIII/00030 and PI21CIII/00039). It was also supported by Plan Nacional de I + D + i 2013–2016, Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (grants RD16CIII/0004/0002, RD16/0016/0001, RD16/0016/0003, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0008, RD16/0016/0010, and RD16/0016/0011). Cofinanced by the European Development Regional Fund “A way to achieve Europe,” Operative Program Intelligent Growth 2014–2020. CIBER – Consorcio Centro de Investigación Biomédica en Red (CB21/13/00095, CB21/13/00012, CB21/13/00049, CB21/13/00054, CB21/13/00055, CB21/13/00068, CB21/13/00081, CB21/13/00084, and CB21/13/00099) (CIBERINFEC) and Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU also supported this work.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Increasing trend of antimicrobial resistance in Shigella associated with MSM transmission in Barcelona, 2020–21: outbreak of XRD Shigella sonnei and dissemination of ESBL-producing Shigella flexneri

  • Moreno-Mingorance, Albert
  • Mir Cros, Alba
  • Goterris Bonet, Lidia
  • Rodríguez Garrido, Virginia
  • Sulleiro, Elena
  • Barberà Gracia, Mª Jesús
  • Descalzo Jorro, Vicente
  • Bravo, Albert
  • Roca, Josep
  • González-López, Juan José
  • Pumarola Suñe, Tomàs
  • VIÑADO, BELEN
  • Larrosa, María Nieves
  • Hoyos Mallecot, Yannick
Antimicrobial resistance; Shigella sonnei; Sexually transmitted infection, Resistencia antimicrobiana; Shigella sonnei; Infección de transmisión sexual, Resistència antimicrobiana; Shigella sonnei; Infecció de transmissió sexual, Background Several countries have recently reported the detection of ESBL-producing Shigella sonnei associated with transmission among MSM. In a previous study by our group, 2.8% of Shigella spp. obtained from MSM in Barcelona between 2015 and 2019 were ESBL producers. Objectives To describe and characterize the emerging ESBL-producing Shigella spp. associated with sexual transmission among MSM detected from 2020 to 2021 in Barcelona, elucidating their connectivity with contemporaneous ESBL-producing Shigella spp. from other countries. Results From 2020 to 2021, we identified that among MSM, 68% of S. sonnei were XDR harbouring blaCTX-M-27 and 14% of Shigella flexneri were MDR harbouring blaCTX-M-27. WGS analysis showed that the ESBL-producing S. sonnei were part of a monophyletic cluster, which included isolates responsible for the prolonged outbreak occurring in the UK. Our data also reveal the first emergence and clonal dissemination of ESBL-producing and fluoroquinolone-resistant S. flexneri 2a among MSM. Conclusions We report an increasing trend of antimicrobial resistance in Shigella spp. among MSM in Barcelona since 2021, mainly as a consequence of the dissemination of XDR ESBL-producing S. sonnei, previously reported in the UK. These results highlight the importance of international collaborative surveillance of MDR/XDR S. sonnei and S. flexneri for rapid identification of their emergence and the prevention of the transmission of these pathogens., This work was partially supported by the ‘Ministerio de Economía y Competitividad’, ‘Instituto de Salud Carlos III’, and co-financed by the European Regional Development Fund (ERDF) ‘A Way to Achieve Europe’ (Spanish Network for Research in Infectious Diseases, grant number RD16/0016/0003) and by the Centro de Investigación Biomédica en Red (CIBER de Enfermedades Infecciosas, grant no. CB21/13/00054). A.M.M. is supported by a grant from the ‘Fondo de Investigación Sanitaria’ (Contratos Predoctorales de Formación en Investigación, grant number FI19/00315).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Population dynamics and antigenic drift of Bordetella pertussis following whole cell vaccine replacement, Barcelona, Spain, 1986–2015

  • Mir Cros, Alba
  • Moreno Mingorance, Albert
  • Martin Gomez, M Teresa
  • Codina Grau, Gema
  • Cornejo Sánchez, Thais
  • Rajadell Guiu, Mireia
  • Rodrigo Gonzalo de Liria, Carlos
  • Pumarola Suñé, Tomàs
  • Fàbrega Santamaría, Anna
  • Gonzalez Lopez, Juan Jose
  • Campins Martí, Magda
MLVA; PFGE; Vacuna contra la tos ferina, MLVA; PFGE, Vacuna contra la tos ferina, MLVA; PFGE; Pertussis vaccine, Among the factors associated with the resurgence of whooping cough, special emphasis has been given to pathogen adaptation after the introduction of the acellular vaccine (ACV). To assess the impact of the vaccine transition strategy from whole-cell vaccine (WCV) to ACV on population dynamics of Bordetella pertussis in Barcelona (Spain), we studied 339 isolates collected from 1986 to 2015 by PFGE and multi-locus variable-number tandem repeat analysis (MLVA). Additionally, allelic variants for the pertussis toxin and its promoter, pertactin, type 3 fimbriae and fimbrial serotyping were assessed to determine its antigenic drift. A shift was observed in the B. pertussis population as well as in its antigenic profile concurrently with the introduction of ACV in Barcelona. Four out of the five most prevalent PFGE profiles were replaced by new profiles following the ACV introduction. MLVA type 27 was the dominant genotype, and its frequency increased from 25% to 79.3% after WCV replacement. Antigen typing demonstrated the emergence of prn2, ptxP3, fim3-2 and a shift from the fimbriae 3 to the fimbriae 2 serotypes after the ACV introduction. Our findings support the presence of population and antigenic dynamic changes in B. pertussis likely driven by the introduction of ACV., This work was supported by the “Ministerio de Economía y Competitividad”, “Instituto de Salud Carlos III”, and cofinanced by the European Regional Development Fun (ERDF) “A Way to Achieve Europe” (Spanish Network for Research in Infectious Diseases [grant number RD16/0016/0003], “Fondo de Investigación Sanitaria [grant number FIS PI18/ 00703]). AMC is supported by the “Agència de Gestió d'Ajuts Universitaris i de Recerca, Generalitat de Catalunya” [grant number 2018FI_B_00855].
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The frequency of defective genomes in Omicron differs from that of the Alpha, Beta and Delta variants

  • Campos Martinez, Carolina
  • Saubí Roca, Narcís
  • Rodríguez Frias, Francisco
  • Rando Segura, Ariadna
  • Colomer-Castell, Sergi
  • Garcia-Cehic, Damir
  • Parés-Badell, Oleguer
  • ADOMBI, Caroline Mélanie
  • QUER, JOSEP
  • Piñana, María
  • González-Sánchez, Alejandra
  • Esperalba, Juliana
  • Codina, María Gema
  • Pumarola Suñe, Tomàs
  • Gregori Font, Josep
  • Esteban Mur, Juan Ignacio
  • BORRAS BERMEJO, BLANCA
  • Ibañez Lligoña, Marta
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Evolution; Genetics; Molecular biology, Evolució; Genètica; Biologia molecular, Evolución; Genética; Biología molecular, The SARS-CoV-2 Omicron variant emerged showing higher transmissibility and possibly higher resistance to current COVID-19 vaccines than other variants dominating the global pandemic. In March 2020 we performed a study in clinical samples, where we found that a portion of genomes in the SARS-CoV-2 viral population accumulated deletions immediately before the S1/S2 cleavage site (furin-like cleavage site, PRRAR/S) of the spike gene, generating a frameshift and appearance of a premature stop codon. The main aim of this study was to determine the frequency of defective deletions in prevalent variants from the first to sixth pandemic waves in our setting and discuss whether the differences observed might support epidemiological proposals. The complete SARS-CoV-2 spike gene was deeply studied by next-generation sequencing using the MiSeq platform. More than 90 million reads were obtained from respiratory swab specimens of 78 COVID-19 patients with mild infection caused by the predominant variants circulating in the Barcelona city area during the six pandemic waves: B.1.5, B.1.1, B.1.177, Alpha, Beta, Delta, and Omicron. The frequency of defective genomes found in variants dominating the first and second waves was similar to that seen in Omicron, but differed from the frequencies seen in the Alpha, Beta and Delta variants. The changing pattern of mutations seen in the various SARS-CoV-2 variants driving the pandemic waves over time can affect viral transmission and immune escape. Here we discuss the putative biological effects of defective deletions naturally occurring before the S1/S2 cleavage site during adaption of the virus to human infection., This study was partially supported by Pla Estratègic de Recerca i Innovació en Salut (PERIS) – Direcció General de Recerca i Innovació en Salut (DGRIS), Catalan Health Ministry, Generalitat de Catalunya; the Spanish Network for the Research in Infectious Diseases (REIPI RD16/0016/0003) from the European Regional Development Fund (ERDF); Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; Grant PI19/00301 from Instituto de Salud Carlos III cofinanced by the European Regional Development Fund (ERDF), and Gilead’s biomedical research project GLD21/00006. We gratefully acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s EpiCov Database on which this research is based.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Rapid and Digital Detection of Inflammatory Biomarkers Enabled by a Novel Portable Nanoplasmonic Imager

  • Belushkin, Alexander|||0000-0003-1928-2223
  • Yesilköy, Filiz|||0000-0001-8483-3285
  • González-López, Juanjo|||0000-0003-2419-5909
  • Ruiz-Rodriguez, Juan Carlos|||0000-0001-7392-8617
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Fàbrega-Santamaria, Anna|||0000-0002-3866-2291
  • Altug, Hatice|||0000-0001-5522-1343
New point-of-care diagnostic devices are urgently needed for rapid and accurate diagnosis, particularly in the management of life-threatening infections and sepsis, where immediate treatment is key. Sepsis is a critical condition caused by systemic response to infection, with chances of survival drastically decreasing every hour. A novel portable biosensor based on nanoparticle-enhanced digital plasmonic imaging is reported for rapid and sensitive detection of two sepsis-related inflammatory biomarkers, procalcitonin (PCT) and C-reactive protein (CRP) directly from blood serum. The device achieves outstanding limit of detection of 21.3 pg mL for PCT and 36 pg mL for CRP, and dynamic range of at least three orders of magnitude. The portable device is deployed at Vall d'Hebron University Hospital in Spain and tested with a wide range of patient samples with sepsis, noninfectious systemic inflammatory response syndrome (SIRS), and healthy subjects. The results are validated against ultimate clinical diagnosis and currently used immunoassays, and show that the device provides accurate and robust performance equivalent to gold-standard laboratory tests. Importantly, the plasmonic imager can enable identification of PCT levels typical of sepsis and SIRS patients in less than 15 min. The compact and low-cost device is a promising solution for assisting rapid and accurate on-site sepsis diagnosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Population dynamics and antigenic drift of Bordetella pertussis following whole cell vaccine replacement, Barcelona, Spain, 1986-2015

  • Mir-Cros, Alba|||0000-0003-4827-9824
  • Moreno Mingorance, Albert|||0000-0002-3073-5046
  • Martin-Gomez, M. Teresa|||0000-0001-8119-8749
  • Codina, María Gema|||0000-0002-5313-5086
  • Cornejo-Sánchez, Thais|||0000-0002-1350-0413
  • Rajadell Guiu, Mireia
  • van Esso, Diego
  • Rodrigo Gonzalo de Líria, Carlos|||0000-0003-1140-2585
  • Campins Martí, Magda|||0000-0002-8841-6195
  • Jané i Checa, Mireia|||0000-0002-1302-6723
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Fàbrega-Santamaria, Anna|||0000-0002-3866-2291
  • González-López, Juanjo|||0000-0003-2419-5909
Among the factors associated with the resurgence of whooping cough, special emphasis has been given to pathogen adaptation after the introduction of the acellular vaccine (ACV). To assess the impact of the vaccine transition strategy from whole-cell vaccine (WCV) to ACV on population dynamics of Bordetella pertussis in Barcelona (Spain), we studied 339 isolates collected from 1986 to 2015 by PFGE and multi-locus variable-number tandem repeat analysis (MLVA). Additionally, allelic variants for the pertussis toxin and its promoter, pertactin, type 3 fimbriae and fimbrial serotyping were assessed to determine its antigenic drift. A shift was observed in the B. pertussis population as well as in its antigenic profile concurrently with the introduction of ACV in Barcelona. Four out of the five most prevalent PFGE profiles were replaced by new profiles following the ACV introduction. MLVA type 27 was the dominant genotype, and its frequency increased from 25% to 79.3% after WCV replacement. Antigen typing demonstrated the emergence of prn2, ptxP3, fim3-2 and a shift from the fimbriae 3 to the fimbriae 2 serotypes after the ACV introduction. Our findings support the presence of population and antigenic dynamic changes in B. pertussis likely driven by the introduction of ACV.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ultrasensitive label-free detection of unamplified multidrug-resistance bacteria genes with a bimodal waveguide interferometric biosensor

  • Maldonado, Jesús
  • González-Guerrero, Ana Belén|||0000-0002-4871-9642
  • Fernandez-Gavela, Adrian|||0000-0002-4562-1308
  • González-López, Juanjo|||0000-0003-2419-5909
  • Lechuga, Laura M.|||0000-0001-5187-5358
Infections by multidrug-resistant bacteria are becoming a major healthcare emergence with millions of reported cases every year and an increasing incidence of deaths. An advanced diagnostic platform able to directly detect and identify antimicrobial resistance in a faster way than conventional techniques could help in the adoption of early and accurate therapeutic interventions, limiting the actual negative impact on patient outcomes. With this objective, we have developed a new biosensor methodology using an ultrasensitive nanophotonic bimodal waveguide interferometer (BiMW), which allows a rapid and direct detection, without amplification, of two prevalent and clinically relevant Gram-negative antimicrobial resistance encoding sequences: the extended-spectrum betalactamase-encoding gene blaCTX-M-15 and the carbapenemase-encoding gene blaNDM-5 We demonstrate the extreme sensitivity and specificity of our biosensor methodology for the detection of both gene sequences. Our results show that the BiMW biosensor can be employed as an ultrasensitive (attomolar level) and specific diagnostic tool for rapidly (less than 30 min) identifying drug resistance. The BiMW nanobiosensor holds great promise as a powerful tool for the control and management of healthcare-associated infections by multidrug-resistant bacteria.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Naturally occurring SARS-CoV-2 gene deletions close to the spike S1/S2 cleavage site in the viral quasispecies of COVID19 patients

  • Andrés, Cristina|||0000-0002-3200-0895
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Piñana, Maria|||0000-0002-4766-2613
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Guerrero Murillo, Mercedes|||0000-0002-5556-2460
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Goterris, Lidia|||0000-0003-1471-4461
  • Codina, María Gema|||0000-0002-5313-5086
  • Quer, Susanna
  • Martín, Maria Carmen
  • Campins Martí, Magda|||0000-0002-8841-6195
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Almirante Gragera, Benito|||0000-0002-1189-2361
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Quer, Josep|||0000-0003-0014-084X
The SARS-CoV-2 spike (S) protein, the viral mediator for binding and entry into the host cell, has sparked great interest as a target for vaccine development and treatments with neutralizing antibodies. Initial data suggest that the virus has low mutation rates, but its large genome could facilitate recombination, insertions, and deletions, as has been described in other coronaviruses. Here, we deep-sequenced the complete SARS-CoV-2 S gene from 18 patients (10 with mild and 8 with severe COVID-19), and found that the virus accumulates deletions upstream and very close to the S1/S2 cleavage site (PRRAR/S), generating a frameshift with appearance of a stop codon. These deletions were found in a small percentage of the viral quasispecies (2.2%) in samples from all the mild and only half the severe COVID-19 patients. Our results suggest that the virus may generate free S1 protein released to the circulation. We suggest that natural selection has favoured a "Don't burn down the house" strategy, in which free S1 protein may compete with viral particles for the ACE2 receptor, thus reducing the severity of the infection and tissue damage without losing transmission capability.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology, Implementation and Clinical Validation

  • Calvo Lozano, Olalla|||0000-0001-5486-2237
  • Sierra, Miquel
  • Soler Aznar, Maria|||0000-0001-7232-2277
  • Estévez, M. Carmen|||0000-0003-3694-7186
  • Chiscano-Camón, Luis|||0000-0003-0037-0610
  • Ruiz-Sanmartin, Adolfo
  • Ruiz-Rodriguez, Juan Carlos|||0000-0001-7392-8617
  • Ferrer, Ricard|||0000-0002-4859-4747
  • González-López, Juanjo|||0000-0003-2419-5909
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Fernandez-Naval, Candela|||0000-0002-5584-3537
  • Bueno, Leticia
  • López-Aladid, Ruben
  • Torres, Antoni|||0000-0002-8643-2167
  • Fernández Barat, Laia|||0000-0001-7528-9636
  • Attoumani, Sarah
  • Charrel, Rémi
  • Coutard, Bruno
  • Lechuga, Laura M.|||0000-0001-5187-5358
Serological tests are essential for the control and management of COVID-19 pandemic (diagnostics and surveillance, and epidemiological and immunity studies). We introduce a direct serological biosensor assay employing proprietary technology based on plasmonics, which offers rapid (<15 min) identification and quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in clinical samples, without signal amplification. The portable plasmonic device employs a custom-designed multiantigen (RBD peptide and N protein) sensor biochip and reaches detection limits in the low ng mL -1 range employing polyclonal antibodies. It has also been implemented employing the WHO-approved anti-SARS-CoV-2 immunoglobulin standard. A clinical validation with COVID-19 positive and negative samples (n = 120) demonstrates its excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor as an accurate and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the disease management and for the evaluation of immunological status during vaccination or treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Foraging at Solid Urban Waste Disposal Sites as Risk Factor for Cephalosporin and Colistin Resistant Escherichia coli Carriage in White Storks (Ciconia ciconia)

  • Höfle, Ursula
  • González-López, Juanjo|||0000-0003-2419-5909
  • Camacho, Maria Cruz
  • Solà-Ginés, Marc
  • Moreno Mingorance, Albert|||0000-0002-3073-5046
  • Manuel Hernández, Jose
  • De la Puente, Javier
  • Pineda-Pampliega, Javier
  • Aguirre, José Ignacio|||0000-0002-0210-890X
  • Torres-Medina, Fernando
  • Ramis Salva, Antonio José|||0000-0001-6755-8066
  • Majó i Masferrer, Natàlia|||0000-0003-0189-9751
  • Blas, Julio
  • Migura-Garcia, Lourdes|||0000-0003-2935-928X
White stork (Ciconia ciconia) may act as a reservoir and vehicle of cephalosporin resistant (CR) Escherichia coli. Between 2011 and 2014, we sampled white storks from colonies exposed to different degrees of anthropic pressure across the major areas of natural distribution of white storks in Spain. Cloacal swab samples (n = 467) were obtained from individuals belonging to 12 different colonies from six different regions. Additionally, 70 samples were collected from recently deposited droppings at the base of nesting platforms. We phenotypically characterized E. coli isolates, confirmed presence of CR genes and classified plasmids. Risk factors for acquiring these genes were assessed. Overall, 8.8% (41 out of 467) storks carried CR E. coli in their cloaca and five (7.1%) were identified from recently deposited droppings; therefore, 46 isolates were further characterized. Of them, 20 contained bla , nine bla , six bla , four bla , three bla , two bla , one bla together with bla , and one bla together with bla . All were multidrug-resistant, and four harbored the plasmid-mediated colistin resistance mcr-1 gene. CR genes were associated with the presence of IncI1, IncFIB, and IncN replicon families. Xba I-macrorestriction analysis revealed a great diversity among most of the Xba I-PFGE types, but indistinguishable types were also seen with isolates obtained from different locations. Clonal complex 10 was the most common among CR E. coli and two bla positive isolates were identified as B2-ST131. Carriage of CR E. coli was significantly higher in colonies located close to solid urban waste disposal sites in which foraging on human waste was more likely and in one case to cattle grazing. The co-occurrence of bla and mcr -1 on plasmids of E. coli isolated from wild birds as early as 2011 is of note, as the earliest previous report of mcr -1 in wild birds is from 2016. Our study shows that foraging at landfills and in association with cattle grazing are important risk factors for the acquisition of CR E. coli in white storks.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Investigational and Experimental Drugs for Community-Acquired Pneumonia, the Current Evidence

  • Sellarès-Nadal, Júlia|||0000-0002-0209-6494
  • Burgos, Joaquín|||0000-0001-8445-3047
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Almirante Gragera, Benito|||0000-0002-1189-2361
Community-acquired pneumonia (CAP) is a common infection with a constantly evolving etiological spectrum. This changing etiology conditions the adequate selection of optimal therapeutic regimens, both in empirical and definitive treatments. In recent years, new antimicrobials have been approved by regulatory authorities for use in CAP, although it is necessary to continue incorporating new antimicrobial agents that improve the activity profile in relation to the appearance of bacterial resistance in certain pathogens, such as pneumococcus, Staphylococcus aureus or Pseudomonas aeruginosa. Delafloxacin, omadacycline and lefamulin are the most recently approved antibiotics for CAP. These three antibiotics have shown non-inferiority to their comparators for the treatment of CAP with an excellent safety profile. However, in the 2019 ATS/IDSA guidelines, it has been considered that more information is needed to incorporate these new drugs into community-based treatment. New antimicrobials, such as solithromycin and nemonoxacin, are currently being studied in Phase III clinical trials. Both drugs have shown non-inferiority against the comparators and an acceptable safety profile; however, they have not yet been approved by the regulatory authorities. Several drugs are being tested in Phase I and II clinical trials. These include zabofloxacin, aravofloxacin, nafithromycin, TP-271, gepotidacin, radezolid, delpazolid, and CAL02. The preliminary results of these clinical trials allow us to assure that most of these drugs may play a role in the future treatment of CAP.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Periprosthetic Joint Infection Prophylaxis in the Elderly after Hip Hemiarthroplasty in Proximal Femur Fractures, Insights and Challenges

  • Rodriguez-Pardo, Dolors|||0000-0001-6781-5405
  • Escolà-Vergé, Laura|||0000-0002-5608-3090
  • Sellarès-Nadal, Júlia|||0000-0002-0209-6494
  • Corona Pérez-Cardona, Pablo S.|||0000-0003-4128-3142
  • Almirante Gragera, Benito|||0000-0002-1189-2361
  • Pigrau, Carlos|||0000-0003-4232-4049
We review antibiotic and other prophylactic measures to prevent periprosthetic joint infection (PJI) after hip hemiarthroplasty (HHA) surgery in proximal femoral fractures (PFFs). In the absence of specific guidelines, those applied to these individuals are general prophylaxis guidelines. Cefazolin is the most widely used agent and is replaced by clindamycin or a glycopeptide in beta-lactam allergies. A personalized antibiotic scheme may be considered when colonization by a multidrug-resistant microorganism (MDRO) is suspected. Particularly in methicillin-resistant Staphylococcus aureus (MRSA) colonization or a high prevalence of MRSA-caused PJIs a glycopeptide with cefazolin is recommended. Strategies such as cutaneous decolonization of MDROs, mainly MRSA, or preoperative asymptomatic bacteriuria treatment have also been addressed with debatable results. Some areas of research are early detection protocols in MDRO colonizations by polymerase-chain-reaction (PCR), the use of alternative antimicrobial prophylaxis, and antibiotic-impregnated bone cement in HHA. Given that published evidence addressing PJI prophylactic strategies in PFFs requiring HHA is scarce, PJIs can be reduced by combining different prevention strategies after identifying individuals who will benefit from personalized prophylaxis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Next-Generation Sequencing for Confronting Virus Pandemics

  • Quer, Josep|||0000-0003-0014-084X
  • Colomer Castell, Sergi|||0000-0002-0307-7455
  • Campos, Carolina|||0000-0002-0132-7027
  • Andrés, Cristina|||0000-0002-3200-0895
  • Piñana, Maria|||0000-0002-4766-2613
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • González Sánchez, Alejandra|||0000-0002-1809-3415
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Ibáñez, Marta|||0000-0001-5185-7467
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Tabernero, David|||0000-0002-1146-4084
Virus pandemics have happened, are happening and will happen again. In recent decades, the rate of zoonotic viral spillover into humans has accelerated, mirroring the expansion of our global footprint and travel network, including the expansion of viral vectors and the destruction of natural spaces, bringing humans closer to wild animals. Once viral cross-species transmission to humans occurs, transmission cannot be stopped by cement walls but by developing barriers based on knowledge that can prevent or reduce the effects of any pandemic. Controlling a local transmission affecting few individuals is more efficient that confronting a community outbreak in which infections cannot be traced. Genetic detection, identification, and characterization of infectious agents using next-generation sequencing (NGS) has been proven to be a powerful tool allowing for the development of fast PCR-based molecular assays, the rapid development of vaccines based on mRNA and DNA, the identification of outbreaks, transmission dynamics and spill-over events, the detection of new variants and treatment of vaccine resistance mutations, the development of direct-acting antiviral drugs, the discovery of relevant minority variants to improve knowledge of the viral life cycle, strengths and weaknesses, the potential for becoming dominant to take appropriate preventive measures, and the discovery of new routes of viral transmission.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The frequency of defective genomes in Omicron differs from that of the Alpha, Beta and Delta variants

  • Campos, Carolina|||0000-0002-0132-7027
  • Colomer Castell, Sergi|||0000-0002-0307-7455
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Andrés, Cristina|||0000-0002-3200-0895
  • Piñana, Maria|||0000-0002-4766-2613
  • González Sánchez, Alejandra|||0000-0002-1809-3415
  • Borras Bermejo, Blanca|||0000-0003-4111-5632
  • Pares Badell, Oleguer|||0000-0003-2568-7550
  • Adombi, Caroline Melanie|||0000-0001-9739-9166
  • Ibañez Lligoña, Marta|||0000-0003-3428-2168
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Codina, María Gema|||0000-0002-5313-5086
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Saubi, Narcis|||0000-0001-5493-1044
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Quer, Josep|||0000-0003-0014-084X
The SARS-CoV-2 Omicron variant emerged showing higher transmissibility and possibly higher resistance to current COVID-19 vaccines than other variants dominating the global pandemic. In March 2020 we performed a study in clinical samples, where we found that a portion of genomes in the SARS-CoV-2 viral population accumulated deletions immediately before the S1/S2 cleavage site (furin-like cleavage site, PRRAR/S) of the spike gene, generating a frameshift and appearance of a premature stop codon. The main aim of this study was to determine the frequency of defective deletions in prevalent variants from the first to sixth pandemic waves in our setting and discuss whether the differences observed might support epidemiological proposals. The complete SARS-CoV-2 spike gene was deeply studied by next-generation sequencing using the MiSeq platform. More than 90 million reads were obtained from respiratory swab specimens of 78 COVID-19 patients with mild infection caused by the predominant variants circulating in the Barcelona city area during the six pandemic waves: B.1.5, B.1.1, B.1.177, Alpha, Beta, Delta, and Omicron. The frequency of defective genomes found in variants dominating the first and second waves was similar to that seen in Omicron, but differed from the frequencies seen in the Alpha, Beta and Delta variants. The changing pattern of mutations seen in the various SARS-CoV-2 variants driving the pandemic waves over time can affect viral transmission and immune escape. Here we discuss the putative biological effects of defective deletions naturally occurring before the S1/S2 cleavage site during adaption of the virus to human infection.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Quantifying In-Host Quasispecies Evolution

  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Ibañez Lligoña, Marta|||0000-0003-3428-2168
  • Quer, Josep|||0000-0003-0014-084X
What takes decades, centuries or millennia to happen with a natural ecosystem, it takes only days, weeks or months with a replicating viral quasispecies in a host, especially when under treatment. Some methods to quantify the evolution of a quasispecies are introduced and discussed, along with simple simulated examples to help in the interpretation and understanding of the results. The proposed methods treat the molecules in a quasispecies as individuals of competing species in an ecosystem, where the haplotypes are the competing species, and the ecosystem is the quasispecies in a host, and the evolution of the system is quantified by monitoring changes in haplotype frequencies. The correlation between the proposed indices is also discussed, and the R code used to generate the simulations, the data and the plots is provided. The virtues of the proposed indices are finally shown on a clinical case.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The burden of non-SARS-CoV2 viral lower respiratory tract infections in hospitalized children in Barcelona (Spain), A long-term, clinical, epidemiologic and economic study

  • Vila, Jorgina|||0000-0001-9715-0627
  • Lera, Esther
  • Andrés, Cristina|||0000-0002-3200-0895
  • Piñana, Maria|||0000-0002-4766-2613
  • Rello-Saltor, Victoria|||0000-0002-7545-6462
  • Tobeña Rue, Marcos|||0009-0004-0798-3238
  • Balcells Ramírez, Joan|||0000-0002-8341-6508
  • Benítez-Díaz, Zaira
  • Aller Hernández, Marta Beatriz|||0000-0002-3344-2329
  • Muñoz, Rosario
  • Vázquez Fariñas, Ana|||0000-0001-6732-1667
  • Rodrigo Gonzalo de Líria, Carlos|||0000-0003-1140-2585
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
Viral lower respiratory tract infections (LRTI) are the leading cause of hospitalization in children. In Catalonia (Spain), information is scarce about the burden of viral LRTIs in paediatric hospitalizations. The aim of this study is to describe epidemiological, clinical, virological and economic features of paediatric hospitalizations due to viral LRTI. From October 2012 to December 2020, children aged <16 years admitted to a tertiary paediatric hospital in Catalonia (Spain) with confirmed viral LRTI were included in the study. Virus seasonality, prevalence, age and sex distribution, clinical characteristics, hospital costs and bed occupancy rates were determined. A total of 3,325 children were included (57.17% male, 9.44% with comorbidities) accounting for 4056 hospitalizations (32.47% ≤ 12 months): 53.87% with wheezing/asthma, 37.85% with bronchiolitis and 8.28% with pneumonia. The most common virus was respiratory syncytial virus (RSV) (52.59%). Influenza A was associated with pneumonia (odds ratio [OR] 7.75) and caused longer hospitalizations (7 ± 31.58 days), while RSV was associated with bronchiolitis (OR 6.62) and was the most frequent reason for admission to the paediatric intensive care unit (PICU) (11.23%) and for respiratory support (78.76%). Male sex, age ≤12 months, chronic conditions and bronchiolitis significantly increased the odds of PICU admission. From October to May, viral LRTIs accounted for 12.36% of overall hospital bed days. The total hospitalization cost during the study period was €16,603,415. Viral LRTIs are an important cause of morbidity, hospitalization and PICU admission in children. The clinical burden is associated with significant bed occupancy and health-care costs, especially during seasonal periods.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Bioinformatic Tools for NGS-Based Metagenomics to Improve the Clinical Diagnosis of Emerging, Re-Emerging and New Viruses

  • Ibañez Lligoña, Marta|||0000-0003-3428-2168
  • Colomer Castell, Sergi|||0000-0002-0307-7455
  • González Sánchez, Alejandra|||0000-0002-1809-3415
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Campos, Carolina|||0000-0002-0132-7027
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Andrés, Cristina|||0000-0002-3200-0895
  • Piñana, Maria|||0000-0002-4766-2613
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Quer, Josep|||0000-0003-0014-084X
Epidemics and pandemics have occurred since the beginning of time, resulting in millions of deaths. Many such disease outbreaks are caused by viruses. Some viruses, particularly RNA viruses, are characterized by their high genetic variability, and this can affect certain phenotypic features: tropism, antigenicity, and susceptibility to antiviral drugs, vaccines, and the host immune response. The best strategy to face the emergence of new infectious genomes is prompt identification. However, currently available diagnostic tests are often limited for detecting new agents. High-throughput next-generation sequencing technologies based on metagenomics may be the solution to detect new infectious genomes and properly diagnose certain diseases. Metagenomic techniques enable the identification and characterization of disease-causing agents, but they require a large amount of genetic material and involve complex bioinformatic analyses. A wide variety of analytical tools can be used in the quality control and pre-processing of metagenomic data, filtering of untargeted sequences, assembly and quality control of reads, and taxonomic profiling of sequences to identify new viruses and ones that have been sequenced and uploaded to dedicated databases. Although there have been huge advances in the field of metagenomics, there is still a lack of consensus about which of the various approaches should be used for specific data analysis tasks. In this review, we provide some background on the study of viral infections, describe the contribution of metagenomics to this field, and place special emphasis on the bioinformatic tools (with their capabilities and limitations) available for use in metagenomic analyses of viral pathogens.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3

  • Cañada-García, Javier E.
  • Moure García, Zaira
  • Sola-Campoy, Pedro J.
  • Delgado-Valverde, Mercedes
  • Cano, María E.
  • Gijón, Desirèe
  • González, Mónica
  • Gracia-Ahufinger, Irene
  • Larrosa, María Nieves|||0000-0001-8808-0233
  • Mulet, Xavier
  • Pitart, Cristina|||0000-0002-3083-7915
  • Rivera, Alba|||0000-0002-9709-6162
  • Bou, German|||0000-0001-8837-0062
  • Calvo, Jorge
  • Cantón, Rafael|||0000-0003-1675-3173
  • González-López, Juanjo|||0000-0003-2419-5909
  • Martínez-Martínez, Luis
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Oliver, Antonio|||0000-0001-9327-1894
  • Palacios-Baena, Zaira R.|||0000-0002-1713-6807
  • Pascual Hernández, Álvaro|||0000-0002-8672-5891
  • Ruiz-Carrascoso, Guillermo
  • Vila Estapé, Jordi|||0000-0002-8025-3926
  • Aracil, Belén
  • Pérez-Vázquez, María
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
Objectives: CARB-ES-19 is a comprehensive, multicenter, nationwide study integrating whole-genome sequencing (WGS) in the surveillance of carbapenemase-producing K. pneumoniae (CP-Kpn) and E. coli (CP-Eco) to determine their incidence, geographical distribution, phylogeny, and resistance mechanisms in Spain. Methods: In total, 71 hospitals, representing all 50 Spanish provinces, collected the first 10 isolates per hospital (February to May 2019); CPE isolates were first identified according to EUCAST (meropenem MIC.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Increasing trend of antimicrobial resistance in Shigella associated with MSM transmission in Barcelona, 2020-21, outbreak of XRD Shigella sonnei and dissemination of ESBL-producing Shigella flexneri

  • Moreno Mingorance, Albert|||0000-0002-3073-5046
  • Mir-Cros, Alba|||0000-0003-4827-9824
  • Goterris, Lidia|||0000-0003-1471-4461
  • Rodríguez Garrido, Virginia|||0000-0001-9870-6201
  • Sulleiro, Elena|||0000-0002-9783-6060
  • Barberà, Maria Jesús|||0000-0002-8259-285X
  • Alberny Iglesias, Mireia
  • Hoyos Mallecot, Yannick|||0000-0002-6354-0149
  • Descalzo Jorro, Vicente
  • Bravo, Albert
  • Roca Grande, Josep|||0000-0002-7177-1684
  • Viñado, Belén|||0000-0001-6212-5886
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Larrosa, María Nieves|||0000-0001-8808-0233
  • González-López, Juanjo|||0000-0003-2419-5909
Several countries have recently reported the detection of ESBL-producing Shigella sonnei associated with transmission among MSM. In a previous study by our group, 2.8% of Shigella spp. obtained from MSM in Barcelona between 2015 and 2019 were ESBL producers. To describe and characterize the emerging ESBL-producing Shigella spp. associated with sexual transmission among MSM detected from 2020 to 2021 in Barcelona, elucidating their connectivity with contemporaneous ESBL-producing Shigella spp. from other countries. From 2020 to 2021, we identified that among MSM, 68% of S. sonnei were XDR harbouring bla and 14% of Shigella flexneri were MDR harbouring bla . WGS analysis showed that the ESBL-producing S. sonnei were part of a monophyletic cluster, which included isolates responsible for the prolonged outbreak occurring in the UK. Our data also reveal the first emergence and clonal dissemination of ESBL-producing and fluoroquinolone-resistant S. flexneri 2a among MSM. We report an increasing trend of antimicrobial resistance in Shigella spp. among MSM in Barcelona since 2021, mainly as a consequence of the dissemination of XDR ESBL-producing S. sonnei, previously reported in the UK. These results highlight the importance of international collaborative surveillance of MDR/XDR S. sonnei and S. flexneri for rapid identification of their emergence and the prevention of the transmission of these pathogens.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems, Recomendaciones del Comité Español del Antibiograma (COESANT) para la selección de antimicrobianos y sus concentraciones en el estudio in vitro de la sensibilidad con métodos automáticos

  • Cantón, Rafael|||0000-0003-1675-3173
  • Oliver, Antonio|||0000-0001-9327-1894
  • Alós, Juan Ignacio
  • Benito, Natividad|||0000-0001-6410-013X
  • Bou, German|||0000-0001-8837-0062
  • Campos, José
  • Calvo, Jorge
  • Canut-Blasco, Andrés
  • Castillo, Javier
  • Cercenado, Emilia|||0000-0002-5279-3773
  • Domínguez, Maria Ángeles
  • Fernández-Cuenca, Felipe
  • Guinea, Jesús
  • Larrosa, María Nieves|||0000-0001-8808-0233
  • Liñares, Josefina
  • López-Cerero, Lorena
  • López-Navas, Antonio
  • Marco, Francesc|||0000-0002-1863-6379
  • Mirelis, Beatriz
  • Moreno-Romo, Miguel Ángel
  • Morosini, María Isabel
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
  • Pascual Leone, Álvaro|||0000-0001-8975-0382
  • Pérez Trallero, Emilio
  • Pérez-Vázquez, María
  • Soriano Viladomiu, Alex|||0000-0002-9374-0811
  • Torres, Carmen
  • Vila Estapé, Jordi|||0000-0002-8025-3926
  • Martínez-Martínez, Luis
Automated antimicrobial susceptibility testing devices are widely implemented in clinical microbiology laboratories in Spain, mainly using EUCAST (European Committee on Antimicrobial Susceptibility Testing) breakpoints. In 2007, a group of experts published recommendations for including antimicrobial agents and selecting concentrations in these systems. Under the patronage of the Spanish Antibiogram Committee (Comité Español del Antibiograma, COESANT) and the Study Group on Mechanisms of Action and Resistance to Antimicrobial Agents (GEMARA) from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), and aligned with the Spanish National Plan against Antimicrobial Resistance (PRAN), a group of experts have updated this document. The main modifications from the previous version comprise the inclusion of new antimicrobial agents, adaptation of the ranges of concentrations to cover the EUCAST breakpoints and epidemiological cut-off values (ECOFFs), and the inference of new resistance mechanisms. This proposal should be considered by different manufacturers and users when designing new panels or cards. In addition, recommendations for selective reporting are also included. With this approach, the implementation of EUCAST breakpoints will be easier, increasing the quality of antimicrobial susceptibility testing data and their microbiological interpretation. It will also benefit epidemiological surveillance studies as well as the clinical use of antimicrobials aligned with antimicrobial stewardship programs., Los sistemas automáticos utilizados en el estudio de la sensibilidad a los antimicrobianos están introducidos en la mayoría de los laboratorios de Microbiología Clínica en España, utilizando principalmente los puntos de corte del European Committee on Antimicrobial Susceptibility Testing (EUCAST). En 2007, un grupo de expertos publicó unas recomendaciones para incluir antimicrobianos y seleccionar concentraciones en estos sistemas. Bajo el auspicio del Comité Español del Antibiograma (COESANT) y del Grupo de Estudio de los Mecanismos de Acción y Resistencia a los Antimicrobianos (GEMARA) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) y alineado con el Plan Nacional frente a la Resistencia a los Antibióticos (PRAN), un grupo de expertos ha actualizado dicho documento. Las principales modificaciones realizadas sobre la versión anterior comprenden la inclusión de nuevos agentes antimicrobianos, la adaptación de los rangos de concentraciones para cubrir los puntos de corte clínicos y los puntos de corte epidemiológicos (ECOFF) definidos por el EUCAST, y para la inferencia de nuevos mecanismos de resistencia. Esta propuesta debería ser considerada por los diferentes fabricantes y los usuarios cuando se diseñen nuevos paneles o tarjetas. Además, se incluyen recomendaciones para realizar informes selectivos. Con este enfoque, la implementación de los puntos de corte del EUCAST será más fácil, aumentando la calidad de los datos del antibiograma y su interpretación microbiológica. También será de utilidad para los estudios de vigilancia epidemiológica, así como para el uso clínico de los antimicrobianos, de acuerdo con los programas de optimización de uso de antimicrobianos (PROA).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Detection of reassortant influenza B strains from 2004 to 2015 seasons in Barcelona (Catalonia, Spain) by whole genome sequencing

  • Andrés, Cristina|||0000-0002-3200-0895
  • del Cuerpo Casas, Margarita|||0000-0001-7973-5496
  • Rabella, Núria|||0000-0002-3409-0468
  • Piñana, Maria|||0000-0002-4766-2613
  • Iglesias Cabezas, Manuel Jesús
  • González Sánchez, Alejandra|||0000-0002-1809-3415
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Martín, Maria Carmen
  • Fuentes, Francisco
  • Rubio, Susana
  • Saubi, Narcis|||0000-0001-5493-1044
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
Influenza B viruses (FLUBV) have segmented genomes which enables the virus to evolve by segment reassortment. Since the divergence of both FLUBV lineages, B/Victoria / 2/87 (FLUBV/VIC) and B/Yamagata/16/88 (FLUBV/YAM), PB2, PB1 and HA have kept the same ancestor, while some reassortment events in the other segments have been reported worldwide. The aim of the present study was to find out reassortment episodes in FLUBV strains detected in cases attended at Hospital Universitari Vall d'Hebron and Hospital de la Santa Creu i Sant Pau (Barcelona, Spain) from 2004 to 2015 seasons. From October 2004 to May 2015, respiratory specimens were received from patients with respiratory tract infection suspicion. Influenza detection was carried out by either cell culture isolation, immunofluorescence or PCR-based assays. A RT-PCR was performed to distinguish both lineages by agarose gel electrophoresis. Whole genome amplification was performed using the universal primer set by Zhou et al. in 2012, and subsequently sequenced using Roche 454 GS Junior platform. Bioinformatic analysis was performed to characterise the sequences with B/Malaysia/2506/2007 and B/Florida/4/2006 corresponding sequences as reference of (B/VIC) and (B/YAM), respectively. A total of 118 FLUBV (75 FLUBV/VIC and 43 FLUBV/YAM), from 2004 to 2006, 2008-2011 and 2012-2015 seasons, were studied. The whole genome of 58 FLUBV/VIC and 42 FLUBV/YAM viruses was successfully amplified. Based on HA sequences, most FLUBV/VIC viruses (37; 64%) belonged to clade 1A (B/Brisbane/60/2008) except to 11 (19%), which fell within clade 1B (B/HongKong/514/2009) and 10 (17%) to B/Malaysia/2506/2004. Nine (20%) FLUBV/YAM viruses belonged to clade 2 (B/Massachusetts/02/2012), 18 (42%) to clade 3 (B/Phuket/3073/2013) and 15 (38%) fell within Florida/4/2006. Numerous intra-lineage reassortments in PB2, PB1, NA and NS were found in 2 2010-2011 viruses. An important inter-lineage reassortment event from 2008 to 2009 (11), 2010-2011 (26) and 2012-2013 (3) FLUBV/VIC (clade 1) strains to FLUBV/YAM (clade 3) was found, in addition to 1 reassortant NS in 2010-2011 B/VIC virus. Intra- and inter-lineage reassortment episodes were revealed by WGS. While PB2-PB1-HA remained in complex, NP and NS reassortant viruses were found in both lineages. Despite reassorment events are not often, the characterisation only by HA and NA sequences might be underestimating their detection.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Increased RSV-A Bronchiolitis Severity in RSV-Infected Children Admitted to a Reference Center in Catalonia (Spain) Between 2014 and 2018

  • Vila, Jorgina|||0000-0001-9715-0627
  • Lera, Esther
  • Peremiquel-Trillas, Paula
  • Andrés, Cristina|||0000-0002-3200-0895
  • Martínez, Laia
  • Barceló, Irene
  • Carsi, Ariadna
  • Balcells Ramírez, Joan|||0000-0002-8341-6508
  • Rodrigo Pendas, Jose Angel|||0000-0003-0400-8766
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Rodrigo Gonzalo de Líria, Carlos|||0000-0003-1140-2585
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
Between 2014 and 2018, we evaluated the severity of 687 cases of bronchiolitis caused by respiratory syncytial virus (RSV) in Catalonia, Spain. Compared to RSV-B, RSV-A cases required intensive care (adjusted relative risk (aRR) = 1.44, p < 0.01) and respiratory support (aRR = 1.07, p < 0.01) more often; hospital stay was one day longer (p < 0.01). Subgroup identification may aid clinical evaluation and seasonal healthcare planning.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections, A Randomized Clinical Trial

  • Sojo-Dorado, Jesús
  • López-Hernández, I.
  • Rosso-Fernandez, C.
  • Palacios-Baena, Z.R.
  • Hernández-Torres, A.
  • Merino de Lucas, Esperanza|||0000-0003-3854-4874
  • Escolà-Vergé, Laura|||0000-0002-5608-3090
  • Bereciartua, Elena|||0000-0002-8603-779X
  • García-Vázquez, E.
  • Pintado, Vicente
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Natera-Kindelán, C.
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Borrell, Nuria
  • Giner-Oncina, L.
  • Amador-Prous, C.
  • Shaw, Evelyn|||0000-0002-1882-1259
  • Jover-Saenz, Alfredo|||0000-0001-5207-7200
  • Molina, J.
  • Martínez-Alvarez, R.M.
  • Dueñas, C.J.
  • Calvo-Montes, J.
  • Silva, J.T.
  • Cárdenes, M.A.
  • Lecuona, M.
  • Pomar, Virginia|||0000-0002-8473-5834
  • Valiente De Santis, L.
  • Yagüe-Guirao, G.
  • Lobo-Acosta, M.A.
  • Merino-Bohórquez, V.
  • Pascual, A.
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • Almirante Gragera, Benito|||0000-0002-1189-2361
  • Mirelis, Beatriz
  • Pigrau, Carlos|||0000-0003-4232-4049
  • Viñado, Belén|||0000-0001-6212-5886
  • Puig-Asensio, Mireia|||0000-0002-0722-2218
  • Ardanuy, Carmen|||0000-0003-0225-607X
  • Pujol, Miquel|||0000-0002-6475-6208
The consumption of broad-spectrum drugs has increased as a consequence of the spread of multidrug-resistant (MDR) Escherichia coli. Finding alternatives for these infections is critical, for which some neglected drugs may be an option. To determine whether fosfomycin is noninferior to ceftriaxone or meropenem in the targeted treatment of bacteremic urinary tract infections (bUTIs) due to MDR E coli. Design, Setting, and Participants: This multicenter, randomized, pragmatic, open clinical trial was conducted at 22 Spanish hospitals from June 2014 to December 2018. Eligible participants were adult patients with bacteremic urinary tract infections due to MDR E coli; 161 of 1578 screened patients were randomized and followed up for 60 days. Data were analyzed in May 2021. Patients were randomized 1 to 1 to receive intravenous fosfomycin disodium at 4 g every 6 hours (70 participants) or a comparator (ceftriaxone or meropenem if resistant; 73 participants) with the option to switch to oral fosfomycin trometamol for the fosfomycin group or an active oral drug or parenteral ertapenem for the comparator group after 4 days. Main Outcomes and Measures: The primary outcome was clinical and microbiological cure (CMC) 5 to 7 days after finalization of treatment; a noninferiority margin of 7% was considered. Among 143 patients in the modified intention-to-treat population (median [IQR] age, 72 [62-81] years; 73 [51.0%] women), 48 of 70 patients (68.6%) treated with fosfomycin and 57 of 73 patients (78.1%) treated with comparators reached CMC (risk difference, -9.4 percentage points; 1-sided 95% CI, -21.5 to ∞ percentage points; P =.10). While clinical or microbiological failure occurred among 10 patients (14.3%) treated with fosfomycin and 14 patients (19.7%) treated with comparators (risk difference, -5.4 percentage points; 1-sided 95% CI, -∞ to 4.9; percentage points; P =.19), an increased rate of adverse event-related discontinuations occurred with fosfomycin vs comparators (6 discontinuations [8.5%] vs 0 discontinuations; P =.006). In an exploratory analysis among a subset of 38 patients who underwent rectal colonization studies, patients treated with fosfomycin acquired a new ceftriaxone-resistant or meropenem-resistant gram-negative bacteria at a decreased rate compared with patients treated with comparators (0 of 21 patients vs 4 of 17 patients [23.5%]; 1-sided P =.01). This study found that fosfomycin did not demonstrate noninferiority to comparators as targeted treatment of bUTI from MDR E coli; this was due to an increased rate of adverse event-related discontinuations. This finding suggests that fosfomycin may be considered for selected patients with these infections. ClinicalTrials.gov Identifier: NCT02142751.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Corrigendum, CARB-ES-19 multicenter study of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli from all Spanish provinces reveals interregional spread of high-risk clones such as ST307/OXA-48 and ST512/KPC-3

  • Cañada-García, Javier E.
  • Moure García, Zaira
  • Sola-Campoy, Pedro J.
  • Delgado-Valverde, Mercedes
  • Cano, María E.
  • Gijón, Desirèe
  • González, Mónica
  • Gracia-Ahufinger, Irene
  • Larrosa, María Nieves|||0000-0001-8808-0233
  • Mulet, Xavier
  • Pitart, Cristina|||0000-0002-3083-7915
  • Rivera, Alba|||0000-0002-9709-6162
  • Bou, German|||0000-0001-8837-0062
  • Calvo, Jorge
  • Cantón, Rafael|||0000-0003-1675-3173
  • González-López, Juanjo|||0000-0003-2419-5909
  • Martínez-Martínez, Luis
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Oliver, Antonio|||0000-0001-9327-1894
  • Palacios-Baena, Zaira R.|||0000-0002-1713-6807
  • Pascual, Álvaro
  • Ruiz-Carrascoso, Guillermo
  • Vila Estapé, Jordi|||0000-0002-8025-3926
  • Aracil, Belén
  • Pérez-Vázquez, María
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
[This corrects the article DOI: 10.3389/fmicb.2022.918362.].
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Periprosthetic Joint Infection Prophylaxis in the Elderly after Hip Hemiarthroplasty in Proximal Femur Fractures: Insights and Challenges

  • Escola Verge, Laura
  • Sellares Nadal, Julia
  • Corona Pérez-Cardona, Pablo Salvador
  • Almirante Gragera, Benito
  • Pigrau Serrallach, Carles
  • Rodríguez Pardo, Ma Dolores
Profilaxi antibiòtica; Hemiartroplàstia de maluc; Infecció periprotèsica de l'articulació, Profilaxis antibiótica; Hemiartroplastia de cadera; Infección de la articulación periprotésica, Antibiotic prophylaxis; Hip hemiarthroplasty; Periprosthetic joint infection, We review antibiotic and other prophylactic measures to prevent periprosthetic joint infection (PJI) after hip hemiarthroplasty (HHA) surgery in proximal femoral fractures (PFFs). In the absence of specific guidelines, those applied to these individuals are general prophylaxis guidelines. Cefazolin is the most widely used agent and is replaced by clindamycin or a glycopeptide in beta-lactam allergies. A personalized antibiotic scheme may be considered when colonization by a multidrug-resistant microorganism (MDRO) is suspected. Particularly in methicillin-resistant Staphylococcus aureus (MRSA) colonization or a high prevalence of MRSA-caused PJIs a glycopeptide with cefazolin is recommended. Strategies such as cutaneous decolonization of MDROs, mainly MRSA, or preoperative asymptomatic bacteriuria treatment have also been addressed with debatable results. Some areas of research are early detection protocols in MDRO colonizations by polymerase-chain-reaction (PCR), the use of alternative antimicrobial prophylaxis, and antibiotic-impregnated bone cement in HHA. Given that published evidence addressing PJI prophylactic strategies in PFFs requiring HHA is scarce, PJIs can be reduced by combining different prevention strategies after identifying individuals who will benefit from personalized prophylaxis., This work was supported by the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación, through the project PI15/02161 and by the Plan Nacional de I+D+i 2013-016 and ISCIIII, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economia, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003)-co-financed by European Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2014–2020.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Quantifying In-Host Quasispecies Evolution

  • Quer Sivila, Josep
  • Gregori Font, Josep
  • Ibañez Lligoña, Marta
Mutagenesis; Quasispecies evolution; Viral treatment, Mutagénesis; Evolución de las cuasiespecies; Tratamiento viral, Mutagènesi; Evolució de les quasiespècies; Tractament viral, What takes decades, centuries or millennia to happen with a natural ecosystem, it takes only days, weeks or months with a replicating viral quasispecies in a host, especially when under treatment. Some methods to quantify the evolution of a quasispecies are introduced and discussed, along with simple simulated examples to help in the interpretation and understanding of the results. The proposed methods treat the molecules in a quasispecies as individuals of competing species in an ecosystem, where the haplotypes are the competing species, and the ecosystem is the quasispecies in a host, and the evolution of the system is quantified by monitoring changes in haplotype frequencies. The correlation between the proposed indices is also discussed, and the R code used to generate the simulations, the data and the plots is provided. The virtues of the proposed indices are finally shown on a clinical case., This study was partially supported by Pla Estratègic de Recerca i Innovació en Salut (PERIS)—Direcció General de Recerca i Innovació en Salut (DGRIS), Catalan Health Ministry, Generalitat de Catalunya; the Spanish Network for the Research in Infectious Diseases (REIPI RD16/0016/0003) from the European Regional Development Fund (ERDF); Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; grant PI19/00301 and PI22/00258 from Instituto de Salud Carlos III cofinanced by the European Regional Development Fund (ERDF), and Gilead’s biomedical research project GLD21/00006.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Host-dependent editing of SARS-CoV-2 in COVID-19 patients

  • Piñana Moro, Maria
  • Campos Martinez, Carolina
  • Garcia Cehic, Damir
  • Codina Grau, Gema
  • Esperalba Esquerra, Juliana
  • Sulleiro Igual, Elena
  • Joseph Munné, Joan
  • Saubí Roca, Narcís
  • Colomer Castell, Sergi
  • Martin Perez, Maria Carmen
  • Castillo Oliveda, Carla
  • Pumarola Suñé, Tomàs
  • Rodríguez Frias, Francisco
  • Quer Sivila, Josep
  • Rando Segura, Ariadna
  • Gregori Font, Josep
  • Esteban Mur, Juan Ignacio
  • Cortese, Maria Francesca
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
SARS-CoV-2; Mutacions; Quasiespècie, SARS-CoV-2; Mutaciones; Cuasiespecie, SARS-CoV-2; Mutations; Quasispecies, A common trait among RNA viruses is their high capability to acquire genetic variability due to viral and host mechanisms. Next-generation sequencing (NGS) analysis enables the deep study of the viral quasispecies in samples from infected individuals. In this study, the viral quasispecies complexity and single nucleotide polymorphisms of the SARS-CoV-2 spike gene of coronavirus disease 2019 (COVID-19) patients with mild or severe disease were investigated using next-generation sequencing (Illumina platform). SARS-CoV-2 spike variability was higher in patients with long-lasting infection. Most substitutions found were present at frequencies lower than 1%, and had an A → G or T → C pattern, consistent with variants caused by adenosine deaminase acting on RNA-1 (ADAR1). ADAR1 affected a small fraction of replicating genomes, but produced multiple, mainly non-synonymous mutations. ADAR1 editing during replication rather than the RNA-dependent RNA polymerase (nsp12) was the predominant mechanism generating SARS-CoV-2 genetic variability. However, the mutations produced are not fixed in the infected human population, suggesting that ADAR1 may have an antiviral role, whereas nsp12-induced mutations occurring in patients with high viremia and persistent infection are the main source of new SARS-CoV-2 variants., This study was supported by the Direcció General de Recerca i Innovació en Salut (DGRIS) of the Catalan Health Ministry, Generalitat de Catalunya, through the Vall d’Hebron Institut de Recerca (VHIR); the European Regional Development Fund (ERDF) “A way to achieve Europe” by the Spanish Network for Research in Infectious Diseases [grant number REIPI RD16/0016/0003]; Instituto de Salud Carlos III [grant number FIS PI19/00301]; and Centro para el Desarrollo Tecnologico Industrial (CDTI) from the Ministry of Economic Affairs and Digital Transformation [grant number IDI-20200297].
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The frequency of defective genomes in Omicron differs from that of the Alpha, Beta and Delta variants

  • Campos Martinez, Carolina
  • Saubí Roca, Narcís
  • Rodríguez Frias, Francisco
  • Rando Segura, Ariadna
  • Colomer-Castell, Sergi
  • Garcia-Cehic, Damir
  • Parés-Badell, Oleguer
  • ADOMBI, Caroline Mélanie
  • QUER, JOSEP
  • Piñana, María
  • González-Sánchez, Alejandra
  • Esperalba, Juliana
  • Codina, María Gema
  • Pumarola Suñe, Tomàs
  • Gregori Font, Josep
  • Esteban Mur, Juan Ignacio
  • BORRAS BERMEJO, BLANCA
  • Ibañez Lligoña, Marta
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Evolution; Genetics; Molecular biology, Evolució; Genètica; Biologia molecular, Evolución; Genética; Biología molecular, The SARS-CoV-2 Omicron variant emerged showing higher transmissibility and possibly higher resistance to current COVID-19 vaccines than other variants dominating the global pandemic. In March 2020 we performed a study in clinical samples, where we found that a portion of genomes in the SARS-CoV-2 viral population accumulated deletions immediately before the S1/S2 cleavage site (furin-like cleavage site, PRRAR/S) of the spike gene, generating a frameshift and appearance of a premature stop codon. The main aim of this study was to determine the frequency of defective deletions in prevalent variants from the first to sixth pandemic waves in our setting and discuss whether the differences observed might support epidemiological proposals. The complete SARS-CoV-2 spike gene was deeply studied by next-generation sequencing using the MiSeq platform. More than 90 million reads were obtained from respiratory swab specimens of 78 COVID-19 patients with mild infection caused by the predominant variants circulating in the Barcelona city area during the six pandemic waves: B.1.5, B.1.1, B.1.177, Alpha, Beta, Delta, and Omicron. The frequency of defective genomes found in variants dominating the first and second waves was similar to that seen in Omicron, but differed from the frequencies seen in the Alpha, Beta and Delta variants. The changing pattern of mutations seen in the various SARS-CoV-2 variants driving the pandemic waves over time can affect viral transmission and immune escape. Here we discuss the putative biological effects of defective deletions naturally occurring before the S1/S2 cleavage site during adaption of the virus to human infection., This study was partially supported by Pla Estratègic de Recerca i Innovació en Salut (PERIS) – Direcció General de Recerca i Innovació en Salut (DGRIS), Catalan Health Ministry, Generalitat de Catalunya; the Spanish Network for the Research in Infectious Diseases (REIPI RD16/0016/0003) from the European Regional Development Fund (ERDF); Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; Grant PI19/00301 from Instituto de Salud Carlos III cofinanced by the European Regional Development Fund (ERDF), and Gilead’s biomedical research project GLD21/00006. We gratefully acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s EpiCov Database on which this research is based.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Increasing trend of antimicrobial resistance in Shigella associated with MSM transmission in Barcelona, 2020–21: outbreak of XRD Shigella sonnei and dissemination of ESBL-producing Shigella flexneri

  • Moreno-Mingorance, Albert
  • Mir Cros, Alba
  • Goterris Bonet, Lidia
  • Rodríguez Garrido, Virginia
  • Sulleiro, Elena
  • Barberà Gracia, Mª Jesús
  • Descalzo Jorro, Vicente
  • Bravo, Albert
  • Roca, Josep
  • González-López, Juan José
  • Pumarola Suñe, Tomàs
  • VIÑADO, BELEN
  • Larrosa, María Nieves
  • Hoyos Mallecot, Yannick
Antimicrobial resistance; Shigella sonnei; Sexually transmitted infection, Resistencia antimicrobiana; Shigella sonnei; Infección de transmisión sexual, Resistència antimicrobiana; Shigella sonnei; Infecció de transmissió sexual, Background Several countries have recently reported the detection of ESBL-producing Shigella sonnei associated with transmission among MSM. In a previous study by our group, 2.8% of Shigella spp. obtained from MSM in Barcelona between 2015 and 2019 were ESBL producers. Objectives To describe and characterize the emerging ESBL-producing Shigella spp. associated with sexual transmission among MSM detected from 2020 to 2021 in Barcelona, elucidating their connectivity with contemporaneous ESBL-producing Shigella spp. from other countries. Results From 2020 to 2021, we identified that among MSM, 68% of S. sonnei were XDR harbouring blaCTX-M-27 and 14% of Shigella flexneri were MDR harbouring blaCTX-M-27. WGS analysis showed that the ESBL-producing S. sonnei were part of a monophyletic cluster, which included isolates responsible for the prolonged outbreak occurring in the UK. Our data also reveal the first emergence and clonal dissemination of ESBL-producing and fluoroquinolone-resistant S. flexneri 2a among MSM. Conclusions We report an increasing trend of antimicrobial resistance in Shigella spp. among MSM in Barcelona since 2021, mainly as a consequence of the dissemination of XDR ESBL-producing S. sonnei, previously reported in the UK. These results highlight the importance of international collaborative surveillance of MDR/XDR S. sonnei and S. flexneri for rapid identification of their emergence and the prevention of the transmission of these pathogens., This work was partially supported by the ‘Ministerio de Economía y Competitividad’, ‘Instituto de Salud Carlos III’, and co-financed by the European Regional Development Fund (ERDF) ‘A Way to Achieve Europe’ (Spanish Network for Research in Infectious Diseases, grant number RD16/0016/0003) and by the Centro de Investigación Biomédica en Red (CIBER de Enfermedades Infecciosas, grant no. CB21/13/00054). A.M.M. is supported by a grant from the ‘Fondo de Investigación Sanitaria’ (Contratos Predoctorales de Formación en Investigación, grant number FI19/00315).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A year living with SARS-CoV-2: an epidemiological overview of viral lineage circulation by whole-genome sequencing in Barcelona city (Catalonia, Spain)

  • Piñana Moro, Maria
  • González Sánchez, Alejandra
  • Garcia Cehic, Damir
  • Esperalba Esquerra, Juliana
  • Zules Oña, Ricardo Gabriel
  • Campos Martinez, Carolina
  • Codina Grau, Gema
  • Blanco Grau, Albert
  • Colomer Castell, Sergi
  • Martin Perez, Maria Carmen
  • Castillo Oliveda, Carla
  • García-Comuñas, Karen
  • Vásquez-Mercado, Rodrigo
  • Martins-Martins, Reginald
  • Saubí Roca, Narcís
  • Pumarola Suñé, Tomàs
  • Quer Sivila, Josep
  • Campins Martí, Magda
  • Rando Segura, Ariadna
  • Borras Bermejo, Blanca
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Catalonia; SARS-CoV-2; Molecular epidemiology, Cataluña; SARS-CoV-2; Epidemiología molecular, Catalunya; SARS-CoV-2; Epidemiologia molecular, Herein, we describe the genetic diversity of circulating SARS-CoV-2 viruses by whole-genome sequencing (WGS) in Barcelona city (Catalonia, Spain) throughout the first four pandemic waves. From weeks 11/2020–24/2021, SARS-CoV-2-positive respiratory samples were randomly selected per clinical setting (80% from primary care or 20% from the hospital), age group, and week. WGS was performed following the ARTICv3 protocol on MiSeq or NextSeq2000 Illumina platforms. Nearly complete consensus sequences were used for genetic characterization based on GISAID and PANGOLIN nomenclatures. From 2475 samples, 2166 (87%) were fully sequenced (78% from primary care and 22% from hospital settings). Multiple genetic lineages were co-circulating, but four were predominant at different periods. While B.1.5 (50.68%) and B.1.1 (32.88%) were the major lineages during the first pandemic wave, B.1.177 (66.85%) and B.1.1.7 (83.80%) were predominant during the second, third, and fourth waves, respectively. Almost all (96.4%) were carrying D614G mutation in the S protein, with additional mutations that define lineages or variants. But some mutations of concern, such as E484K from B.1.351 and P.1 lineages are currently under monitoring, together with those observed in the receptor-binding domain or N-terminal domain, such as L452R and T478K from B.1.617.2 lineage. The fact that a predominant lineage was observed in each pandemic wave suggests advantageous properties over other contemporary co-circulating variants. This genetic variability should be monitored, especially when a massive vaccination campaign is ongoing because the potential selection and emergence of novel antigenic SARS-CoV-2 strains related to immunological escapement events., This work was supported by Spanish Network for the Research in Infectious Diseases: [Grant Number REIPI RD16/0016/0003]; Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business [Grant Number IDI-20200297]; Direcció General de Recerca i Innovació en Salut (DGRIS); European Development Regional Fund (ERDF) “A way to achieve Europe” by Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/0003].
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Population dynamics and antigenic drift of Bordetella pertussis following whole cell vaccine replacement, Barcelona, Spain, 1986–2015

  • Mir Cros, Alba
  • Moreno Mingorance, Albert
  • Martin Gomez, M Teresa
  • Codina Grau, Gema
  • Cornejo Sánchez, Thais
  • Rajadell Guiu, Mireia
  • Rodrigo Gonzalo de Liria, Carlos
  • Pumarola Suñé, Tomàs
  • Fàbrega Santamaría, Anna
  • Gonzalez Lopez, Juan Jose
  • Campins Martí, Magda
MLVA; PFGE; Vacuna contra la tos ferina, MLVA; PFGE, Vacuna contra la tos ferina, MLVA; PFGE; Pertussis vaccine, Among the factors associated with the resurgence of whooping cough, special emphasis has been given to pathogen adaptation after the introduction of the acellular vaccine (ACV). To assess the impact of the vaccine transition strategy from whole-cell vaccine (WCV) to ACV on population dynamics of Bordetella pertussis in Barcelona (Spain), we studied 339 isolates collected from 1986 to 2015 by PFGE and multi-locus variable-number tandem repeat analysis (MLVA). Additionally, allelic variants for the pertussis toxin and its promoter, pertactin, type 3 fimbriae and fimbrial serotyping were assessed to determine its antigenic drift. A shift was observed in the B. pertussis population as well as in its antigenic profile concurrently with the introduction of ACV in Barcelona. Four out of the five most prevalent PFGE profiles were replaced by new profiles following the ACV introduction. MLVA type 27 was the dominant genotype, and its frequency increased from 25% to 79.3% after WCV replacement. Antigen typing demonstrated the emergence of prn2, ptxP3, fim3-2 and a shift from the fimbriae 3 to the fimbriae 2 serotypes after the ACV introduction. Our findings support the presence of population and antigenic dynamic changes in B. pertussis likely driven by the introduction of ACV., This work was supported by the “Ministerio de Economía y Competitividad”, “Instituto de Salud Carlos III”, and cofinanced by the European Regional Development Fun (ERDF) “A Way to Achieve Europe” (Spanish Network for Research in Infectious Diseases [grant number RD16/0016/0003], “Fondo de Investigación Sanitaria [grant number FIS PI18/ 00703]). AMC is supported by the “Agència de Gestió d'Ajuts Universitaris i de Recerca, Generalitat de Catalunya” [grant number 2018FI_B_00855].
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3

  • Sola-Campoy, Pedro Juan
  • Delgado-Valverde, Mercedes
  • Cano, María E.
  • Gijón, Desirèe
  • Larrosa Escartin, María Nieves
  • Gonzalez Lopez, Juan Jose
  • Cañada-Garcia, Javier E.
  • Moure Garcia, Zaira
Carbapenemases; High-risk clones; Whole genome sequencing, Carbapenemasas; Clones de alto riesgo; Secuenciación del genoma completo, Carbapenemases; Clons d'alt risc; Seqüenciació del genoma sencer, Objectives: CARB-ES-19 is a comprehensive, multicenter, nationwide study integrating whole-genome sequencing (WGS) in the surveillance of carbapenemase-producing K. pneumoniae (CP-Kpn) and E. coli (CP-Eco) to determine their incidence, geographical distribution, phylogeny, and resistance mechanisms in Spain. Methods: In total, 71 hospitals, representing all 50 Spanish provinces, collected the first 10 isolates per hospital (February to May 2019); CPE isolates were first identified according to EUCAST (meropenem MIC > 0.12 mg/L with immunochromatography, colorimetric tests, carbapenem inactivation, or carbapenem hydrolysis with MALDI-TOF). Prevalence and incidence were calculated according to population denominators. Antibiotic susceptibility testing was performed using the microdilution method (EUCAST). All 403 isolates collected were sequenced for high-resolution single-nucleotide polymorphism (SNP) typing, core genome multilocus sequence typing (cgMLST), and resistome analysis. Results: In total, 377 (93.5%) CP-Kpn and 26 (6.5%) CP-Eco isolates were collected from 62 (87.3%) hospitals in 46 (92%) provinces. CP-Kpn was more prevalent in the blood (5.8%, 50/853) than in the urine (1.4%, 201/14,464). The cumulative incidence for both CP-Kpn and CP-Eco was 0.05 per 100 admitted patients. The main carbapenemase genes identified in CP-Kpn were blaOXA–48 (263/377), blaKPC–3 (62/377), blaVIM–1 (28/377), and blaNDM–1 (12/377). All isolates were susceptible to at least two antibiotics. Interregional dissemination of eight high-risk CP-Kpn clones was detected, mainly ST307/OXA-48 (16.4%), ST11/OXA-48 (16.4%), and ST512-ST258/KPC (13.8%). ST512/KPC and ST15/OXA-48 were the most frequent bacteremia-causative clones. The average number of acquired resistance genes was higher in CP-Kpn (7.9) than in CP-Eco (5.5). Conclusion: This study serves as a first step toward WGS integration in the surveillance of carbapenemase-producing Enterobacterales in Spain. We detected important epidemiological changes, including increased CP-Kpn and CP-Eco prevalence and incidence compared to previous studies, wide interregional dissemination, and increased dissemination of high-risk clones, such as ST307/OXA-48 and ST512/KPC-3., This research was supported by grants from the Instituto de Salud Carlos III (numbers PI18CIII/00030 and PI21CIII/00039). It was also supported by Plan Nacional de I + D + i 2013–2016, Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (grants RD16CIII/0004/0002, RD16/0016/0001, RD16/0016/0003, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0008, RD16/0016/0010, and RD16/0016/0011). Cofinanced by the European Development Regional Fund “A way to achieve Europe,” Operative Program Intelligent Growth 2014–2020. CIBER – Consorcio Centro de Investigación Biomédica en Red (CB21/13/00095, CB21/13/00012, CB21/13/00049, CB21/13/00054, CB21/13/00055, CB21/13/00068, CB21/13/00081, CB21/13/00084, and CB21/13/00099) (CIBERINFEC) and Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU also supported this work.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Bioinformatic Tools for NGS-Based Metagenomics to Improve the Clinical Diagnosis of Emerging, Re-Emerging and New Viruses

  • Colomer Castell, Sergi
  • González Sánchez, Alejandra
  • Campos Martinez, Carolina
  • Garcia Cehic, Damir
  • Piñana Moro, Maria
  • Pumarola Suñé, Tomàs
  • Rodríguez Frias, Francisco
  • Quer Sivila, Josep
  • Gregori Font, Josep
  • Ibañez Lligoña, Marta
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Diagnostic tools; Metagenomics; Viruses, Herramientas diagnosticas; Metagenómica; Virus, Eines diagnòstiques; Metagenòmica; Virus, Epidemics and pandemics have occurred since the beginning of time, resulting in millions of deaths. Many such disease outbreaks are caused by viruses. Some viruses, particularly RNA viruses, are characterized by their high genetic variability, and this can affect certain phenotypic features: tropism, antigenicity, and susceptibility to antiviral drugs, vaccines, and the host immune response. The best strategy to face the emergence of new infectious genomes is prompt identification. However, currently available diagnostic tests are often limited for detecting new agents. High-throughput next-generation sequencing technologies based on metagenomics may be the solution to detect new infectious genomes and properly diagnose certain diseases. Metagenomic techniques enable the identification and characterization of disease-causing agents, but they require a large amount of genetic material and involve complex bioinformatic analyses. A wide variety of analytical tools can be used in the quality control and pre-processing of metagenomic data, filtering of untargeted sequences, assembly and quality control of reads, and taxonomic profiling of sequences to identify new viruses and ones that have been sequenced and uploaded to dedicated databases. Although there have been huge advances in the field of metagenomics, there is still a lack of consensus about which of the various approaches should be used for specific data analysis tasks. In this review, we provide some background on the study of viral infections, describe the contribution of metagenomics to this field, and place special emphasis on the bioinformatic tools (with their capabilities and limitations) available for use in metagenomic analyses of viral pathogens., This study was partially supported by Pla Estratègic de Recerca i Innovació en Salut (PERIS)—Direcció General de Recerca i Innovació en Salut (DGRIS), Catalan Health Ministry, Generalitat de Catalunya; the Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003) from the European Regional Development Fund (ERDF); Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; grants PI19/00301 and PI22/00258 from Instituto de Salud Carlos III, cofinanced by the European Regional Development Fund (ERDF); and Gilead’s biomedical research project GLD21/00006. S.C-C is a recipient of a predoctoral fellowship, FPU, from Ministerio de Universidades (FPU21/04150).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The burden of non-SARS-CoV2 viral lower respiratory tract infections in hospitalized children in Barcelona (Spain): A long-term, clinical, epidemiologic and economic study

  • Vila Soler, Jorgina
  • Lera Carballo, Esther
  • Piñana Moro, Maria
  • Rello Saltor, Victoria
  • Tobeña Rue, Marc
  • Balcells Ramirez, Joan
  • Benítez Díaz, Zaira
  • Aller Hernández, Marta Beatriz
  • Muñoz Gallarin, Rosario
  • Vázquez, Ana
  • Rodrigo Gonzalo de Liria, Carlos
  • Soler Palacín, Pere
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Cost of illness; Hospitalization; Viruses, Cost de la malaltia; Hospitalització; Virus, Coste de la enfermedad; Hospitalización; Virus, Background Viral lower respiratory tract infections (LRTI) are the leading cause of hospitalization in children. In Catalonia (Spain), information is scarce about the burden of viral LRTIs in paediatric hospitalizations. The aim of this study is to describe epidemiological, clinical, virological and economic features of paediatric hospitalizations due to viral LRTI. Methods From October 2012 to December 2020, children aged <16 years admitted to a tertiary paediatric hospital in Catalonia (Spain) with confirmed viral LRTI were included in the study. Virus seasonality, prevalence, age and sex distribution, clinical characteristics, hospital costs and bed occupancy rates were determined. Results A total of 3,325 children were included (57.17% male, 9.44% with comorbidities) accounting for 4056 hospitalizations (32.47% ≤ 12 months): 53.87% with wheezing/asthma, 37.85% with bronchiolitis and 8.28% with pneumonia. The most common virus was respiratory syncytial virus (RSV) (52.59%). Influenza A was associated with pneumonia (odds ratio [OR] 7.75) and caused longer hospitalizations (7 ± 31.58 days), while RSV was associated with bronchiolitis (OR 6.62) and was the most frequent reason for admission to the paediatric intensive care unit (PICU) (11.23%) and for respiratory support (78.76%). Male sex, age ≤12 months, chronic conditions and bronchiolitis significantly increased the odds of PICU admission. From October to May, viral LRTIs accounted for 12.36% of overall hospital bed days. The total hospitalization cost during the study period was €16,603,415. Conclusions Viral LRTIs are an important cause of morbidity, hospitalization and PICU admission in children. The clinical burden is associated with significant bed occupancy and health-care costs, especially during seasonal periods., This work was partially supported by the Spanish National R + D + I Plan 2008–2011 and by the Carlos III Health Institute, the Subdirectorate-General of Networks and Cooperative Research Centers, the Spanish Ministry of Economy and Competitiveness, the Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003), and by the Health Research Fund, the Spanish Ministry of Economy and Competitiveness (grants FIS PI14/01838 and FIS PI18/00685), and the European Regional Development Fund (ERDF). Editorial assistance for revision of the English language and edition of the manuscript was provided by Vanessa Marfil, medical writer from MSC (Spain) and funded by Sanofi.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Next-Generation Sequencing for Confronting Virus Pandemics

  • Quer Sivila, Josep
  • Colomer Castell, Sergi
  • Campos Martinez, Carolina
  • Piñana Moro, Maria
  • González Sánchez, Alejandra
  • Garcia Cehic, Damir
  • Pumarola Suñé, Tomàs
  • Rodríguez Frias, Francisco
  • Tabernero, David
  • Ibañez Lligoña, Marta
  • Cortese, Maria Francesca
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
COVID-19; Pandemics; Viruses, COVID-19; Pandemias; Virus, COVID-19; Pandèmies; Virus, Virus pandemics have happened, are happening and will happen again. In recent decades, the rate of zoonotic viral spillover into humans has accelerated, mirroring the expansion of our global footprint and travel network, including the expansion of viral vectors and the destruction of natural spaces, bringing humans closer to wild animals. Once viral cross-species transmission to humans occurs, transmission cannot be stopped by cement walls but by developing barriers based on knowledge that can prevent or reduce the effects of any pandemic. Controlling a local transmission affecting few individuals is more efficient that confronting a community outbreak in which infections cannot be traced. Genetic detection, identification, and characterization of infectious agents using next-generation sequencing (NGS) has been proven to be a powerful tool allowing for the development of fast PCR-based molecular assays, the rapid development of vaccines based on mRNA and DNA, the identification of outbreaks, transmission dynamics and spill-over events, the detection of new variants and treatment of vaccine resistance mutations, the development of direct-acting antiviral drugs, the discovery of relevant minority variants to improve knowledge of the viral life cycle, strengths and weaknesses, the potential for becoming dominant to take appropriate preventive measures, and the discovery of new routes of viral transmission., Pla Estratègic de Recerca i Innovació en Salut (PERIS)—Direcció General de Recerca i Innovació en Salut (DGRIS), Catalan Health Ministry, Generalitat de Catalunya; the Spanish Network for the Research in Infectious Diseases (REIPI RD16/0016/0003) from the European Regional Development Fund (ERDF; Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; grant GLD21_00006; and grant PI19/00301 from Instituto de Salud Carlos III cofinanced by the European Regional Development Fund (ERDF).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology: Implementation and Clinical Validation

  • Calvo Lozano, Olalla
  • Sierra Montoya, Miquel
  • Soler, Maria
  • Estevez, M. Carmen
  • Chiscano Camon, Luis Silvestre
  • Ruiz Sanmartin, Adolfo
  • Ruiz Rodriguez, Juan Carlos
  • Ferrer Roca, Ricard
  • Gonzalez Lopez, Juan Jose
  • Esperalba Esquerra, Juliana
  • Fernandez Naval, Candela
COVID-19; Biosensor plasmónico; Serología, COVID-19; Biosensor plasmònic; Serologia, COVID-19; Plasmonic biosensor; Serology, Serological tests are essential for the control and management of COVID-19 pandemic (diagnostics and surveillance, and epidemiological and immunity studies). We introduce a direct serological biosensor assay employing proprietary technology based on plasmonics, which offers rapid (<15 min) identification and quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in clinical samples, without signal amplification. The portable plasmonic device employs a custom-designed multiantigen (RBD peptide and N protein) sensor biochip and reaches detection limits in the low ng mL–1 range employing polyclonal antibodies. It has also been implemented employing the WHO-approved anti-SARS-CoV-2 immunoglobulin standard. A clinical validation with COVID-19 positive and negative samples (n = 120) demonstrates its excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor as an accurate and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the disease management and for the evaluation of immunological status during vaccination or treatment., ICN2 and UVE acknowledge financial support from H2020 Research and Innovation Programme of the European Commission (H202-SC1-PHE-Coronavirus-2020, CONVAT Project, No. 101003544). The ICN2 is funded by the CERCA program/Generalitat de Catalunya and supported by the Severo Ochoa Centres of Excellence program funded by the Spanish Research Agency (AEI, grant no. SEV-2017-0706). ICN2 group is very grateful to EPI Industries (Barcelona, Spain) for its kind donation supporting our research in COVID-19. O.C.-L. acknowledges the economic support from the Spanish Ministry of Science and Innovation and the Spanish Research Agency and the European Social Fund (ESF) (ref. BES-2017-080527) linked to the TEC 2016-78515-R project Predict. A part of the work was supported by the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the EU Horizon 2020 (grant agreement No. 871029). A.T. and L.F.-B. acknowledge financial support from GENCAT-DGRIS COVID. We are indebted to all the patients who accepted to participate contributing to science advancement. We are indebted to the HCB-IDIBAPS Biobank for the human samples and data procurement and to the Fundació Glòria Soler for its support to the COVIDBANK collection. We thank the IDIBAPS Biobank for its valuable contribution to sample processing and storage. The authors acknowledge the EU Horizon 2020 Program under grant agreement no. 644956 (RAIS project) for funding the Hospital Vall d’Hebron Biobank. The VHIR-HUVH is supported by Plan Nacional de I + D + i 2013-2016 and ISCIII-Ministerio de Ciencia e Innovación, and Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003)─cofinanced by European Development Regional Fund “A way to achieve Europe,” Operative program Intelligent Growth 2014. Part of the samples and data from patients included in this study were provided by the Vall d’Hebron University Hospital Biobank (PT17/0015/0047), integrated in the Spanish National Biobanks Network, and they were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committee. The authors kindly appreciate the generous donation of samples and clinical data of the donors of the Sepsis Bank of HUVH Biobank and COVID-19 patients attended at HUVH.